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ABSTRACT

REGULATION OF THE INSULIN-LIKE GROWTH FACTOR SYSTEM BY
RETINOIC ACID IN HUMAN OSTEOBLAST CELLS

by
Yuehua Zhou

Retinoic acid (RA) is an important regulator of growth and differentiation in many
cell types, including bone. However, its effects on human osteoblast cell growth and
differentiation have not been well studied. Therefore, I investigated the effect of RA on
proliferation and differentiation of normal human bone cells (HBCs) and human
osteosarcoma, SaOS-2 cells. RA decreased baseline as well as serum-stimulated
proliferation in normal HBCs. To determine the effect of RA on differentiation, expression
of several osteoblastic differentiation markers were studied. RA decreased type I
procollagen mRNA levels and l,25(OH)2D3-stimulated osteocalcin and alkaline
phosphatase (ALP) mRNA levels as well as baseline and l,25(OH)2D3-stimulated ALP
activity. These results indicate that RA inhibits human osteoblast cell proliferation and
differentiation.
The insulin-like growth factor (IGF) system is an important local regulator of
bone cell proliferation and differentiation. The actions of IGF are mediated through IGF
receptors and are modulated by six IGF binding proteins (IGFBPs) which either inhibit or
enhance IGF action. The effect of RA on the IGF system in HBCs has not yet been
determined. Therefore, because RA inhibits and IGFs stimulate proliferation and
differentiation, I tested the hypothesis that RA inhibits HBC growth and differentiation by
down-regulating the IGF system. Adthough the expression of IGF-II (the predominant IGF

in HBCs) was not decreased by RA, cell surface binding of IGF-I and IGF-II as well as
IGF-I receptor expression were decreased by RA. Furthermore RA increased expression
of inhibitory IGFBP-3, -4 and -6 and decreased the expression of stimulatory IGFBP-5.
These results indicate that RA markedly down-regulated the IGF system.
To investigate the mechanism(s) by which RA regulated IGFBP expression, the
effect of RA on mRNA stability of each IGFBP was studied. RA moderately increased the
mRNA stabilities of IGFBP-3, -4, -5 and -6, which could explain the small increase in
IGFBP-3 and -4 steady-state mRNA levels, but could not explain the dramatic decrease in
IGFBP-5 mRNA levels and increase in IGFBP-6 mRNA levels. By using quantitative
RT-PCR analysis, I found that RA increased nascent IGFBP-6 transcripts by a mechanism
dependent on protein synthesis. These results suggest that RA regulates the expression of
IGFBP-3 and -4 primarily by delayed post-transcriptional and IGFBP-5 and -6 primarily
by transcriptional or early post-transcriptional mechanisms.
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CHAPTER ONE
I. INTRODUCTION
A. Retinoids
1.

Structure, Biogenesis and Metabolism
(1) Structure
Retinoids are a group of natural and synthetic compounds that are structurally related

to retinol (vitamin A). In 1982, the International Union of Pure and Applied
Chemistry-International Union of Biochemistry (lUPAC-IUB) Joint Commission on
Biochemical Nomenclature defined retinoids as a class of compounds consisting of four
isoprenoid units joined in a head-to-tail manner. Retinoids were derived from a
monocyclic parent compound containing five carbon-carbon double bonds and a functional
group at the terminus of the acyclic portion.
The structure of a retinoid is relatively simple. A six-membered ionylidene ring is
linked to a polyene chain containing four conjugated double bonds. The ring as well as
the polyene chain can carry various functional groups. In addition, each of the double
bonds can assume either a cis or a tram conformation. Because retinoids contain four
double bonds, a total of 16 stereoisomers can form, but some of these isomers are
unstable. In addition to naturally occurring retinoids, there are hundreds of synthetic
retinoid analogs. Similar to natural retinoids, synthetic analogs consist of a lipophilic
moiety at one end of the molecule, a polar group at the opposite end and a largely
hydrophobic spacer connecting these two parts (Spom et al., 1994).
(2) Active metabolites
A\\-tram retinol is intracellularly metabolized via a series of oxidation and
isomerization reactions to three active retinoids: zW-tram RA, 3,4-didehydro-RA (Thaller
et al., 1990) and 9-cis RA (Heyman et al., 1992) (Fig. 1). AX\-tram retinol is first oxidized
to a\[-tram retinaldehyde, which in turn is oxidized to all-tram RA. 3,4-didehydro-RA is
1
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synthesized from all-/ram1 retinol by dehydrogenation followed by two subsequent
oxidation reactions similar to those involved in the biosynthesis of ?X\-trans RA. The
existence of 9-cis RA in cells was reported simultaneously by Levin et al. (1992) and by
Heyman et al. (1992). Levin demonstrated that this stereoisomer was the activating
ligand for RXR-a in COS-1 cells. Heyman reported that 9-cis RA was a ligand for the
human RXR-a. 9-cis RA also exists in mouse liver (Heyman et al., 1992). 9-cis RA, a
stereoisomer of a\\-trans RA, is generated by intracellular isomerization of all-/mm' RA.
The formation of 9-cis RA, either by isomerization of the all-/ram-isomer or by cleavage
of 9-c/s-carotenoids, may be an important mechanism for retinoid signaling.
(3) Biogenesis and metabolism of retinoids
The vitamin A requirements of humans are derived either from carotenoids of plant
origin or from "preformed" vitamin A of animal origin. Approximately 50 of the 600 or
more carotenoids found in nature are converted to vitamin A. The most active of them is
all-/mm-(3-carotene (Fig. 1). Two pathways for this conversion exist in mammals: (1) a
central oxidative cleavage of carotenoids to retinal, followed by reduction to retinol, and
(2) a excentric oxidative cleavage via a series of (3-apocarotenals to retinal, followed by
reduction to retinol (Glover, 1960). The predominant pathway of converting
p-carotene into retinal is the central cleavage pathway in liver and intestinal mucosa
(Goodman et al., 1965; Olson et al., 1965).
Vitamin A (retinol) is released from liver and circulates in the plasma bound to retinol
binding protein (RBP) (Blaner, 1989). Retinol is taken up by target cells and serves as the
metabolic precusor of biologically active RAs (Napoli et al., 1993). The metabolic
process of retinol conversion to active metabolites involves cellular retinol binding
proteins (CRBPs) and RA binding proteins (CRABPs) (Ong, 1987; Giguere, 1994).
CRBP-I binds to retinol with high affinity and is widely expressed in adult tissues whereas
CRBP-H expression is restricted to the small intestine (Levin et al., 1987). Cells

5

expressing CRBP metabolize retinol to RA by a process that includes oxidation of retinol
to retinaldehyde which in turn is oxidized to RA by aldehyde dehydrogenase (ADH) or
oxidase. The conversion of retinol to RA could occur within cells of liver, testis (Leo et
al, 1984; Napoli et al., 1987), kidney (Posch et al., 1991), intestinal mucosa (Molfa et al.,
1970), lung (Bhat et al., 1988) and ocular tissue (Lion et al., 1975). Evidence of this
conversion in osteoblasts has not yet been obtained. Newly synthesized RA could then act
by endocrine, autocrine and paracrine mechanisms. Cells expressing more cellular RA
binding protein-I (CRABP-I) would catabolize ?X\-tram RA toward more polar
metabolites, such as 9-cis RA, and thus display a more limited response to all-/ram' RA.
In addition to their role in all-/ram RA catabolism, CRABPs sequester all-/ram RA in the
cytoplasm thus preventing it from reaching the nucleus and interacting with nuclear
receptors. CRBPs and CRABPs, therefore, play important role in retinoid signaling by
controlling the intracellular concentrations and types of RA metabolites.

2.

Mechanisms of Retinoid Action
(1) The RAR and RXR nuclear receptor superfamily
The classical action of RA is to bind to specific nuclear receptors and act as

transcription factors to regulate target gene expression. Retinoid receptors show striking
structural and functional similarity to steroid hormone receptors and belong to the nuclear
hormone receptor superfamily (Chambon et al., 1991). The steroid hormone receptors are
organized into several distinct regions (domains) (Fig. 2). The most conserved domain is
the DNA-binding domain. The two zinc-cysteine fingers contained within the DNA
binding domain interact with the specific DNA sequence which forms the response
element (Luisi et al., 1991). The ligand-binding domains in the receptors from the same
family are approximately 85% identical. There are two well recognized families of nuclear
retinoic acid receptors: the Retinoic Acid Receptors (RARs) and Retinoid X Receptors
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(RXRs). Both RARs and RXRs are ligand-inducible transcriptional regulators which
activate or inhibit transcription by interacting with Retinoic Acid Response Elements
(RAREs) or Retinoid X Response Elements (RXREs).
There are three RAR subtypes: RAR-a, RAR-(3 and RAR-y and each subtype can
give rise to one to four isoforms that differ in the amino-terminal region by differential
usage of two promoters and alternative RNA splicing (Giguere, 1994). The ligand binding
domains of RARs are highly conserved (>75% amino acid identity), suggesting that they
arise from a common ancestral RAR gene. The RARs bind to dW-trcms RA or 9-cis RA.
The RAR isoforms are expressed in distinct patterns throughout development and in the
mature organism (Ruberte et al., 1991; Nagpal et al., 1992), indicating that they mediate
embryogenic as well as normal metabohc cellular functions. Thus, the diversity of effects
of retinoids on cells can be partly explained by the diversity of dS\-trans RA receptors.
The RXRs bind specifically to 9-cis RA with high afiBnity. There are three RXR
subtypes: RXR-a, RXR-(3 and RXR-y which are encoded by separate genes at distinct
chromosomal loci. These subtypes were identified in mammals, birds and amphibians
(Levin et al., 1992; Heyman et al., 1992; Allenby et al., 1993). The RXR proteins are
closely related structurally both in their DNA-binding and ligand-binding domains. The
expression of RXRs is developmentally regulated. At early stages of mouse
embryogenesis, RXR-a and RXR-j3 are expressed while in late mouse organogenesis and
in adult tissues, expression of RXR-a becomes more restricted, produced predominantly
in the skin, liver and digestive tract epithelia (Mangelsdorf et al., 1992).
Several laboratories have identified so-called orphan receptors, that is, nuclear
receptors whose ligands are yet unknown but based on DNA and amino acid sequence
identity belong to the nuclear receptor superfamily (Giguere et al., 1994). The RZR
family of orphan receptors is structurally simihar to the RXR family of receptors. RZR-a
is expressed in many tissues while RZR-(3 is only expressed in the brain. RZRs show
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constitutive transactivational activity that can be enhanced by unidentified components in
fetal calf serum (Carlberg et al., 1994).
(2) RA response elements and responsive genes
(a) RA response elements
RARs and RXRs differentially modulate gene expression by binding as homodimers
or heterodimers to short DNA sequences termed RAREs and RXREs, respectively (Fig.
3). Although RA response elements could mediate different responses, they share a
concensus sequence "PuG(G/T)TCA" which can be arranged in direct repeats (DR),
everted repeats (ER) and palindromes as shown in Table 1. Most RAREs identified to
date exist as repeats of the core sequence "PuG(G/T)TCA" spaced by 5 bps (DR-5)
(Giguere, 1994). In addition, direct repeats of the core motif separated by 2 bps (DR-2)
can also operate efficiently as RAREs (William et al., 1992; Rottman et al., 1991). RARs
also recognize RAREs composed of everted repeats of the core half-site motif
"PuGGTCA" spaced by 8 bps (Tini et al., 1993) and bind to complex elements composed
of direct or inverted repeats of the "PuG(G/T)TCA" motif separated by spacers of variable
length (Richard et al., 1991). All these RARE configurations are shown in Table 1.
Among them, RAREs of the DR-5 class are generally more potent in transactivation than
are other types. A limited number of RXREs identified exist as direct repeats spaced by 1
bp (DR-1) (Smith et al., 1991). DR-1 response elements are targets of a number of other
orphan nuclear receptors that include chicken ovalbumin upstream promoter transcription
factor (COUP-TF), peroxisome proliferator-activated receptor (PPAR) and RZR
(Giguere, 1994; Glass, 1994). The diversity of the RAREs and RXREs with their distinct
configurations lead to varying levels of potency and specificity. This constitutes yet
another means to increase the complexity of the retinoid response at the level of gene
transcription.

o

Figure 3. The retinoid signal transduction pathway. RA functions in a manner analogous to the other Hpid-soluble hormones
such as steroids, thyroid hormone, and vitamin D. The blood-home hormone (H) can penetrate the cell membrane and bind to an
intracellular receptor (R). Unlike membrane-receptor second-messenger systems, in this pathway the liganded receptor itself
becomes the signal to the nucleus, where it interacts with hormone response elements (HREs) in the target gene to elicit a
transcriptional response. Essential features of this model have been proven to be correct. This figure is adapted from " The
Retinoids: Biology, Chemistry and Medicine" by Spom et al. (1994).
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Table 1. Retinoic acid response elements (RAREs & RXREs)
Sequence

Type

Gene

DR-1

rCRBP-II

>
ACAGGTCACAGGTCACA

mCRABP-II

>
GAAGGGCAGAGGTCACA

rCRBP-I

GTAGGTCAAAAAGTCAGA

mCRBP-I

GTAGGTCAAAAGGTCAGA

hRARp2

>
AGGGTTCACCGAAAGTTCACT

hRARa2

GAGGTTCAGCGAGAGTTCAGC

hRARy2

CCGGGTCAGGAGGAGGTGAGC

ER-8

hMCAD

ATTGACCTTTCTCTCCGGGTAAAG

Palindrome

TREpal

TCAGGTCATGACCTGA

bGH

GGGGGACATGACCCCA

rGH

>
AAAGGTAAGATCAGGGACGTGACCGCA

DR-2

DR-5

Conqjlex

* This table is adapted from Giguere (1994).
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(b) RA-responsive genes
A large number of the RA-responsive genes characterized to date encode proteins
that participate in the transduction of the retinoid signal. All three RAR genes contain
RAREs in their promoters (Leroy et al, 1991; Munoz-Canoves et al., 1990). This
autoinduction of RAR expression could lead to an amplification of the RA signal.
Activation of CRBP-I (Smith et al., 1991) and ADH3 (Duester et al., 1991) genes by
zW-trans RA could lead to an increase in all-/ram' RA synthesis. Up-regulation of the
CRABP-II gene may result in the all-/ram RA response (Durand et al., 1992). On the
other hand, not all RA responsive genes are involved in RA signal transduction or
amplification. Hox genes are regulated by all-/ram RA during embryogenesis and their
promoters contain DR-5 RAREs (Langston et al., 1992). Growth hormone (GH) mRNA
expression is up-regulated by all-/ram RA and its promoter contains a palindromic or
complex RARE sequence (Wilhams et al., 1992; Umesono et al., 1988).
(3) Hormone receptor mediated transcriptional regulation
The expression of genes containing RAREs or RXREs can be regulated positively or
negatively by RAR and RXR homodimers or heterodimers (Richard et al., 1991;
Nicholson et al., 1990). Transcription rates are increased by RA through the interaction
of specific receptors with an RARE. Transcription rates in other genes with RAREs are
down-regulated after RA treatment through mechanisms involving receptor interference
with other, positive-acting transcription factors, such as AP-1.
(a) Interaction with other steroid hormone receptors
RXRs form heterodimers with other members of the nuclear receptor superfamily,
such as the RARs, the vitamin D receptor (VDR), the thyroid receptor (TR) and the
COUP-TF and activate transcription through DR-3, DR-4, DR-2 or DR-5 hormone
response elements (HREs), respectively (Liao et al. 1990; Murray et al., 1989; Glass et
al., 1990; Yang et al., 1991). This interaction requires only the cognate VDR or TR
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ligands and is not dependent upon binding of tbe RXR ligand, 9-cis RA. An example of
this interaction in bone cells occurs in the proximal promoter of the rat osteocalcin gene
(MacDonald et al., 1993). It was reported that l,25(OH)2D3-activated expression of this
gene was stimulated by the RXR but was inhibited by 9-cis RA. Transcription from the
osteocalcin gene was stimulated by l,25(OH)2D3-induced heterodimerization of the VDR
and the unliganded RXR. 9-cis RA attenuates l,25(OH)2D3 responsiveness by diverting
the ligand bound RXRs away from the VDR and toward other RXR-dependent
transcriptional pathways. It was found that the COUP-TF-RXR or RAR-RXR
heterodimers functions as potent repressors of RXR-mediated transactivation.
The dual functions of the RXR as both a ligand-dependent transcription factor
(homodimer) and as an active partner to several nuclear receptors (heterodimer) are
complex. Further complexity is generated as a consequence of potential crosstalk between
these pathways (Mangelsdorf et al., 1991). For example, at high 9-cis RA concentrations,
the RXR homodimer is stabilized and binds to a DR-1 RXRE and thus favors activation of
RXR target genes, such as CRBP-II. In the presence of low concentrations of 9-cis RA,
the RXR-RAR heterodimer has a higher affinity for the DR-1 RARE than does the RXR
homodimer. Therefore, the heterodimer preferentially binds to the CRBP-II DR-1 RXRE
and results in transcriptional repression of CRBP-II (Durand et al., 1992). The
physiological implications of the multifunctional RXR either as an independent receptor
for 9-cis RA or as a promiscuous partner interacting with a multitude of HREs remains to
be investigated. Transcriptional interference between different nuclear receptor pathways
could result from competition for limiting amounts of RXR, activation of the RXR
pathways with 9-cis RA, or formation of unproductive heterodimeric complexes (Giguere,
1994).
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(b) Interaction with AP-1
Recent studies indicate that the activity of retinoid receptors may be modulated by
other nuclear transcription factors, such as AP-1. AP-1 is a complex formed from the
proto-oncoprotein Jun and Fos family members (Angel et al., 1987). AP-1 activity is
stimulated by tumor promoters and growth factors. In the human osteocalcin gene, it was
shown that agents which stimulate AP-1 synthesis block d\\-traris RA actions, reciprocally,
treatment with d\\-tram RA can inhibit AP-1 actions (Schule et al., 1990). An AP-1
binding site resides in the proximity of the VDRE and RARE in the rat and human
osteocalcin promoter (Schule et al., 1990). Although the mechanism of this mutual
inhibition by aW-trans RA and AP-1 is not yet clear, it has been suggested that the two
different classes of transcription factors interact with a common response element. Simple
occupancy of the AP-1 binding site prevents nuclear receptor binding (Schule et al.,
1990). The RAR represses AP-1 responsive genes, such as the rat collagenase gene by
another mechanism (Schule et al., 1991; Nicholson et al., 1990). This mechanism of
repression of the collagenase promoter involves direct protein-protein interactions
between the RAR and AP-1. It has been proposed that the RAR may form a
nonproductive complex with c-Jun, thereby inhibiting AP-1 transactivation and providing
a simple mechanism by which RA may limit cell growth and possibly malignant
progression. In contrast, the RXR does not display this AP-1 inhibitory activity.
(4) Post-transcriptional regulation
A number of studies have shown that steroid hormones alter steady-state mRNA
levels through unidentified post-transcriptional mechanisms often requiring protein factors
which stabilize or destabilize cytoplasmic mRNAs (Lee et al., 1988; Nielsen et al., 1990;
Kyeyune-Nyombi et al., 1991). Most recently, Zhou et al. (1994) have identified a novel
early post-transcriptional RA regulatory mechanism in rat preosteoblast UMR-201 cells in
which RA increases ALP nascent chain abundance. Nascent ALP chains accumulated in
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the nuclear matrix after 24 h of RA treatment. It is not clear whether this mechanism is a
receptor-mediated process. This novel post-transcriptional RA stimulated mechanism
plays an important role in determining the steady-state ALP mRNA level.
(5) Post-translational regulation
A novel pathway that is distinct from receptor-mediated transactivation has been
recently described to explain RA-induced differentiation of murine embryonal carcinoma
F9 cells (Kitabayashi et al., 1994). F9 cell differentiation was not blocked after inhibition
of protein synthesis and mRNA synthesis during RA treatment. During the commitment
of the F9 cells to RA-induced c-jun expression, which is a differentiation marker for F9
cells, at least five sets of proteins underwent changes in their phosphorylation states in the
absence of de novo protein synthesis or mRNA synthesis (Kitabayashi et al., 1994).
Therefore, increased protein phosphorylation is another pathway which can in part
mediate the effect of RA.
In summary, there are several different mechanisms by which RA modulates gene
expression. The most common mechanism is to change the rate of gene transcription with
specific nuclear receptors (Levin et al., 1992). More recently, a post-transcriptional
mechanism involving changes in RNA stability or processing has been shown to be
important (Zhou et al., 1994). An RA-associated change at the level of transcription
could result either from a direct or indirect effect of RA. Direct effects of RA through
nuclear receptors on gene transcription are generally assumed to be elicited without de
novo protein synthesis. The effects are rapid, might involve phosphorylation and are
mediated by direct binding of RARs or RAR-RXR complexes to an RARE. The RAR-a,
-{3 and -y receptors are directly and rapidly activated through RAREs in their promoter
(Richard et al., 1991). In cases of indirect regulation, trans-activation results in
transcription rate changes at a later time. In this case, RA activates expression of a
transcription factor, which then regulates the RA-responsive gene.
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3.

Effects of Retinoids
(1) Retinoids in embryogenesis
The formation of an organism from an egg involves cellular growth, differentiation

and rearrangement. Retinoids act as regulators of embryonic development by affecting
growth, differentiation and cell movement. A good example is the initiation of limb bud
development in the embryo which involves the process of cell proliferation, differentiation
and pattern formation.
Limb bud formation is initiated in the embryo by the continued local proliferation of
cells of the lateral plate mesoderm at the appropriate axial levels at the time of cessation of
rapid growth of cells in the rest of the flank. In avian and mammalian limb bud initiation,
the rapid division of mesodermal cells is controlled by fibroblast growth factors (FGFs).
RA is thought to induce FGF production (Tabin, 1995). In addition to initiating limb bud
outgrowth, the presumptive limb mesoderm carries essential information for establishing
anterior-posterior polarity of the limb bud. Within the developing limb bud, a specialized
region at the posterior margin of the bud, called the zone of polarizing activity (ZPA), is
believed to be responsible for normal pattern specification along the anterior-posterior axis
of the limb bud. It was found that ZPA taken from a mouse, human, hamster or turtle
could induce pattern duplication of the chick wing buds (Tickle, 1980). To test the
hypothesis that ZPA produced a morphogen that difliises into the limb bud and sets up a
concentration gradient, Tickle et al. (1975; 1982) found that the local margin of the chick
wing bud induced the same type of digit duplications as ZPA grafts. When implanted at
the anterior margin of the chick wing bud, di\[-tram RA induced pattern changes in a
dose-dependent fashion which were identical to those caused by ZPA grafts in the same
location (Tickle et al., 1982). In addition, Wolport (1969) demonstrated that a natural
gradient of RA had roughly the same diftusion slope as that of the postulated ZPA
morphogen. Based on the above observations, RA has been widely accepted as the long
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sought-after ZPA morphogen. Identification of the gene networks controlled by RA are
now the focus of many new studies.
Retinoids have long been recognized as potent teratogens for mammahan embryos.
Exposing developing mouse embryos to zW-tram RA induces reproducible changes in the
axial organization of the vertebrae (Kessel et al., 1991; 1992). It was found that the
morphological changes induced by zll-trans RA are often accompanied by changes in
expression of the developmental control homeobox gene family, Hox (Langston et al.,
1992). The homeobox is a 183 bp motif of DNA which encodes a 61 amino acid protein
domain that folds into a helix-tum-helix motif capable of sequence-specific DNA binding
(McGinnis et al., 1992). Hox genes are typically expressed in tissue domains with sharp
anterior boundaries and progressively weaker posterior expression boundaries (Kessel et
al., 1991), consistent with the graded distribution of endogenous polarizing potential
(Hombruch et al., 1991). Therefore, Hox proteins are reasonable candidates for the
components regulating polarizing potential. In addition, the regionalized pattern of
expression of Hox genes in transgenic mice argues for the involvement of these genes in
the specification of axial structures (Kessel et al., 1990). Hox genes of groups 1-8,
including Hoxb-8, are known to be inducible by RA in vitro (Mavilio et al., 1988).
Tight control of RA receptor expression is maintained in the embryo to either quickly
amplify an aW-trans RA signal or to suppress it. Actions of a\\-tram RA on RA receptor
expression are mediated transcriptionally through stimulatory or inhibitory RAREs and
RXREs in all three RA receptor genes. Therefore, RARs are expressed spatially and
temporally under strict control during mouse embryogenesis. For example, RAR-(3 is
expressed in the tracheal, intestinal and genital tract epitheha, suggesting that it plays a
major role in differentiation of specific epithelial structures during development. The
distribution of RAR-y supports a role for this receptor in chondrogenesis and
differentiation of squamous and mucous epitheha (Dolle et al., 1990; Ruberte et al., 1991;
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Mangelsdorf et al., 1992; Rowe et al., 1991; Noji et al, 1989; Dolle et al., 1989; Ruberte
et al., 1990; Osumi et al., 1990; Mendelsohn et al., 1992).
Taken together, RA plays an important role in embryogenesis and morphogenesis not
only by initiating development of various tissues by modulating cell proliferation and
differentiation but also by controlling spatial rearrangements through mechanisms that
have not been defined but may involve selective activation and expression of RA receptor,
Hox and growth factor genes.
(2) Retinoids in adult tissue maintenance
Adult tissue maintenance involves selective stimulation of cell proliferation and
differentiation to renew tissue and organ systems. In animal studies, it was found that an
adequate supply of vitamin A is essential for the control of normal cellular proliferation
and differentiation (Wolbach, 1993). For example, animals deficient in vitamin A are more
susceptible to chemical carcinogens than are nondeficient animals (Roger et al., 1973;
Cohan et al., 1976). Cancer is a disease of uncontrolled cell growth and a loss of
differentiated fimctions. Exogenous administration of retinoids inhibits or reverses
carcinogen-induced changes in a variety of target tissues (Hicks, 1983; Moon et al., 1984).
Since retinoids regulate or control cell proliferation and differentiation, they are prime
candidates for use in cancer chemoprevention.
Many studies have begun to define the mechanisms whereby RA exerts control over
cellular proliferation and differentiation in the adult organism. Growth and differentiation
are affected by a number of circulating hormones and growth factors. The net activity of
both stimulatory and inhibitory hormones and growth factors regulate cell proliferation
and differentiation. Therefore, inhibition of growth by RA has been linked to enhancement
of the activities of growth inhibitory or differentiation promoting proteins, such as the
TGF-{3 family (Spom et al., 1994). The TGF-(3 family are multifunctional peptides whose
actions often parallel the actions of RA and thus could be recruited to mediate RA effects.
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Both agents are potent inhibitors of the growth of epithehal cells (Glick et al., 1989), both
agents have similiar effects on the synthesis of matrix proteins and related proteases and
protease inhibitors (Clark et al., 1987; Quinn et al., 1994) and both agents can stimulate
expression of receptors for epidermal growth factor (EGF) (Thompson et al., 1989). It
was found that RA stimulated the secretion of TGF-(32 in primary murine keratinocytes
(Glick et al., 1989), human lung carcinoma A-549 cells and normal rat kidney NRK
fibroblasts (Danielpour et al., 1991), and stimulated the secretion of TGF-|32 and -(53 in
primary cultures of chicken embryo chondrocytes, myocytes and fibroblasts (Jakowlew et
al., 1992). hi each of these systems, the induction of TGF-P expression was posttranscriptional (Glick et al., 1988). No evidence for direct transcriptional regulation of
TGF-P expression by RA has been found (Kim et al., 1989). The growth inhibition of
HL-60 promyelocytic leukemia cells with RA is associated with increased expression of
not only TGF-P but also its receptors (Rizzino et al., 1987). In rare cases, the action of
RA and TGF-P can also be antagonistic. For example, RA and TGF-P have distinctly
different effects on limb formation. RA induces duplication of the digits (Thaller et al.,
1987), while TGF-p treatment results in deletion of specific skeletal elements of the
developing limb (Hayamizu et al., 1991).
The mitogenic actions of EGF and TGF-a are believed to be mediated through an
EGF-receptor (EGF-R) (Spom et al., 1994). Regulation of EGF-R expression is variable
and tissue specific but when expressed, the EGF-R has a significant influence on cell
growth in vivo and in vitro. Suppressive effects of retinoids on EGF-R synthesis correlate
with inhibitory effects of retinoids on cell growth and conversely, cells that become
resistant to the growth-inhibitory effects of retinoids were also insensitive to regulation of
the EGF-R by retinoids (Steck et al., 1990). Developmental studies also demonstrated
variable effects of retinoids on the expression of EGF-R (Abbott et al., 1988). Although
the effects of RA on EGF-R are different, several lines of evidence suggest that RA
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directly regulates transcription of the EGF-R, regardless of whether the effects are
stimulatory or inhibitory. For example, in fetal rat lung cells and NRK rat kidney
fibroblasts, RA increased EGF-R mRNA expression transcriptionally while in human
epidermoid carcinoma ME 180 cells, EGF-R expression was suppressed by RA through
negative regulatory elements in the EGF-R promoter (Zheng et al., 1992). In addition to
the effects of RA on EGF-R expression, most in vitro studies using human breast cancer
cells (Fontana et al., 1992) and human embryonal cancer cells (Miller et al., 1990) show
that RA supresses TGF-a expression.
IGFs are mitogenic peptides that play an important role in bone cell growth and
differentiation as well as in numerous other cell types. RA decreased the expression of
IGF-I mRNA in rat glioma C6 cells, in parallel with its suppressive effects on the growth
of the same cells (Lowe et al., 1992). In constrast, RA stimulated the expression of IGFII mRNA and protein in human neuroblastoma cells, even though the growth of these cells
was also inhibited by RA (Matsumoto et al., 1992). Studies of its effects on human breast
cancer cells and on rat hepatocytes and osteoblasts indicated that RA can also regulate the
activity of IGFs indirectly, by regulating the expression of their binding proteins, IGFBP-1
through -6 (Fontana et al., 1991, Schmid et al., 1992).
Taken together, these studies show that RA can recruit a variety of growth factors
and their receptors to mediate its actions and most of the effects of RA on growth factor
and binding protein activities are consistent with their suppressive action on cell growth.
Therefore, it is important to study the effect of RA on growth factor expression in adult
cells to elucidate the mechanism(s) for growth regulation and to ultimately use this
information to develop cancer chemopreventive therapies.
(3) Retinoids in coupling of bone formation and resorption
Bone has two major functions, mechanical support and an important metabolic role in
mineral homeostasis by transferring calcium and other ions into and out of the skeletal
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reservior. Both of these functions are intimately related to hone volume which is
maintained through a continuous balance, ie., a coupling between bone formation and
bone resorption (Schiltz et al., 1991). Resorption is initiated by multinucleated osteoclasts
which are responsible for removing both mineral and organic components of the matrix.
Formation is a process in which osteoprogenitor cells proliferate and differentiate to
become mature osteoblast cells. The coupling is thought to be mediated by local growth
factors which act as paracrine/autocrine effectors of bone formation and have been
demonstrated to increase osteoblast proliferation and bone matrix biosynthetic activity
(Mohan et al., 1984). The coupling is also affected by hormones, such as PTH (Donahue
et al., 1989), l,25(OH)2D3 (Linkhart et al., 1989) and RA (Wolbach, 1947).
Studies on the mechanism of RA action using in vitro cell culture systems revealed
that RA affects both osteoblast cell proliferation and differentiation, two major processes
that lead to hone formation. RA inhibits rat osteosarcoma (Ng et al., 1985), human
osteosarcoma and chondrosarcoma (Thein et al., 1982) cell proliferation. RA either
stimulates or inhibits osteoblast cell differentiation depending on the differentiation stage
of the cells and the model system tested. For example, ALP activity, osteocalcin
secretion, ALP and type I procollagen mRNA levels were increased by RA in
undifferentiated rat calvarial derived UMR-201 cells (Ng et al., 1988), rat osteosarcoma
ROS 17/2 cells (Nishimoto et al., 1987) and SV-40 transformed embryonic rat calvariae,
RCT-1 and RCT-3 cells (Heath et al., 1989). In contrast, RA inhibited ALP activity in the
differentiated rat osteoblast-like cell line, ROS 17/2.8 (Imai et al., 1988), and reduced
collagen synthesis in chick (Dickson et al., 1985) and rat (Varghese et al, 1994) primary
calvarial cell cultures. These studies on osteoblast phenotype marker proteins collectively
suggest that RA is an important modulator of osteoblast cell differentiation in rat model
systems, however, the effect of RA on human osteoblasts has not yet been studied.
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Early studies have demonstrated a decrease in bone and cartilage resorption in dogs
and rats that are vitamin A deficient (Mellanby, 1944). An increase in resorption was
found in young rats receiving large doses of fish liver oil concentrate and crystalline
vitamin A (Bamicot et al., 1972), suggesting that bone lesions were caused by
hypervitaminosis A. Therefore, it was concluded that one of the functions of vitamin A
was to stimulate bone and cartilage resorption. The actions of vitamin A to increase bone
resorption were thought to be mediated directly by osteoclasts which possess a CRABP
(Teti et al., 1986) and not by production of other known bone resorhers, such as PTH
(Hough et al., 1988). In vivo experiments with animals (dog, guinea pig and rat) having
hypervitaminosis A, revealed that when young animals were treated with vitamin A,
longitodinal long bone growth was inhibited (Wolbach, 1947). Changes in shape of long
bones were observed which were interpreted as resulting from a combination of excessive
bone resorption at some sites and failure to grow new bone at others (Wolbach, 1947;
Bamicot et al., 1972). Therefore, vitamin A not only increased bone resorption but also
inhibited bone formation. More recently, in vitro experiments with fetal rat calvariae
cultures have shown that RA increases collagenase synthesis and collagen degradation
(Quian et al., 1989; Varghese et al., 1994), supporting the hypothesis that osteoblast
mediated bone formation is affected by RA. Taken together, RA acts on bone remodeling
by decreasing bone formation and increasing bone resorption. The effects of RA on
human bone remains to be defined.

B. Insulin-Like Growth Factor (IGF) System
The IGF system consists of four known components: IGFs, IGF receptors, IGF
binding proteins (IGFBPs) and IGFBP-specific proteases. Changes in expression of IGFs,
the IGF receptors and IGFBPs affect cell proliferation (Schiltz et al., 1991) and recent
studies indicates that changes in these IGF system components also affect differentiation in
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several cell types including myoblasts (Bach et al., 1994) and osteoblasts (Rosen et al.,
1994). The contribution of newly discovered IGFBP proteases (Hossenlopp et al., 1990)
to IGF system effects has not yet been determined and will not be discussed as part of the
IGF system.

1.

IGFs
IGF-I and IGF-II are single polypeptide growth factors with molecular weights of 7.6

and 7.5 kDa, respectively. These proteins share 60% amino acid sequence similarity and
have structural and functional homology to insulin (Rinderknecht et al., 1978a; 1978b).
(1) IGF-I
The human IGF-I gene is located on chromosome 12 and is approximately 90 kb in
length (Tricoh et al., 1984; Sussenbach, 1989). Two mRNA transcripts (IGF-IA and
IGF-IB) produced by alternative splicing are expressed in a defined pattern in most tissues
during pre- or post-natal development. The highest expression is observed in adult liver
(Han et al., 1988; D'Ercole et al., 1991). Growth hormone (GH) is a major regulator,
enhancing IGF-I gene expression in the liver and cartilage (Roberts et al., 1986; Hynes et
al., 1987; Murphy et al., 1987). In addition to GH, other hormones and trophic factors
affect IGF-I expression. Thyroid hormone (TH) (Wolf et al., 1989), EGF (Rogers et al.,
1991), parathyroid hormone (PTH) (Linkhart et al., 1989), cortisol (McCarthy et al.,
1989) and dexamethasone (Luo et al., 1989) affect IGF-I expression or GH-induced IGF-I
expression. IGF-I stimulates proliferation and differentiation of cells in many tissues,
including rat and human bone (Varghese et al., 1994; Rosen et al., 1994; Wergedal et al..
1990).
(2) IGF-H
The human IGF-II gene contains eight exons distributed over 30 kb DNA and is
located on the short arm of chromosome 11 (Brissenden et al., 1984; Bell et al., 1985;
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Sussenbach et al., 1989). Like IGF-I, the IGF-II gene is transcribed and processed into
several different mRNA species (4.9, 5.3, 6.0 kb) resulting from alternative promoter
usage and alternative RNA splicing (Schneid et al., 1993; Daughaday et al., 1989). In rats
and mice the level of IGF-II in serum is higher during fetal than during post-natal life
(Moses et al., 1980; Daughaday et al., 1982; Brown et al., 1986), while in humans and
guinea pigs a substantial concentration of IGF-II remains in the adult serum (Enberg et al.,
1984; Daughaday et al., 1986). Hormones and tissue-specific factors regulate IGF-II gene
expression in selected tissues (Voutilainen et al., 1987). Human ovarian granulosa cells in
culture accumulate IGF-II mRNA and secrete IGF-II in response to follicle stimulating
hormone (FSH), chorionic gonadotropin and prolactin (Voutilainen et al., 1987;
Ramasharma et al., 1987). Primary human adrenal cells respond to adrenocorticotrophic
hormone (ACTH) by increasing steady-state levels of IGF-II mRNA (Voutilainen et al.,
1987). The mechanisms involved in the regulation of IGF-II expression are incompletely
defined. Nielson et al. (1990) have shown that among several IGF-II mRNA species,
only mRNAs containing the non-coding exon 6 are translated into polypeptide, suggesting
that translational competency for IGF-II is determined by the 5'-untranslated region
(S’-UTR). IGF-D promotes cellular proliferation, differentiation and glucose metabolism
(Rosen et al., 1994).
(3) IGFs and bone
IGFs significantly affect bone formation by increasing osteoblast proliferation and
activity. Osteoblasts synthesize and secrete the IGFs, however, the relative distribution of
IGF-I and IGF-II are different in human and rodent systems. Human osteoblast cells
secrete significant amounts of IGF-II but IGF-I production is undectable in most systems
(Mohan et al., 1990). However, cultured rat and mouse bone cells produce more IGF-I
(several-fold) than IGF-II (Mohan et al., 1991; Varghese et al., 1994). IGF-I and IGF-II
are potent mitogens for bone cells in fetal rat calvaria (McCarthy et al, 1989; Varghese et

26

al., 1994), murine osteoblast-like cells (Merriman et al., 1990; Stein et al., 1993) and
cultured human bone cells (HBCs) (Baylink et al, 1993). Besides their mitogenic action
on osteoblasts, IGFs increase osteoblast activity. Type I procollagen synthesis was
increased in rat calvariae by IGF-I (Hock et al., 1988) and in untransformed HBCs by
IGF-n (Strong et al., 1991). In rat calvarial cultures, IGF-I increased production of
osteocalcin (Canalis et al., 1988) while in human osteosarcoma cells, neither IGF-I nor
IGF-II alone induced osteocalcin synthesis. However, both IGF-I and IGF-II interacted
synergistically with l,25(OH)2D3to increase osteocalcin production in rat and human
osteoblast-like cells (Fournier et al., 1993). Both IGF-I and IGF-II stimulate ALP activity
(Schmid et al., 1984). In addition, IGFs can inhibit expression of specific interstitial
collagenases thus preventing type I collagen degradation (Daughaday et al., 1987). Taken
together, these data suggest that both IGF-I and IGF-II are potent stimulators of bone
formation.

2.

IGF Receptors
The biological effects of IGFs are mediated through IGF receptors on the cell surface.

There are two structurally and functionally distinct IGF receptors.
(1) Type I IGF receptor
The type I IGF receptor binds to IGF-I with a 15 to 20 fold higher affinity than to
IGF-II and a much lower affinity to insulin (Germain-Lee et al., 1992). The type I IGF
receptor is a disulfide bond linked heterotetrameric protein (a2p2) in which the a subunit
(-130 kDa) contains the ligand binding domain and the b subunit (-90 kDa) contains a
transmembrane domain and an intracellular domain with tyrosine kinase activity (Ullrich et
al., 1986; Kasuga et al., 1981; Massague et al., 1982). The type I IGF receptor gene is
located on chromosome 15 (Ullrich et al., 1986). From the cDNA sequence, it was found
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that the insulin and IGF-I receptor tyrosine kinase domain shared 84% sequence identity
(Ullrich et al., 1985; Kasuga et al., 1981; Massague et al., 1982).
Several lines of evidence suggest that the IGF-I receptor can mediate the effects of
both IGF-I and IGF-II (Redder et al., 1990). However, as described below, both IGF-I
and -II receptors can act independently to affect bone cell metabohsm. Comparison of
dose-response curves of IGF-I and IGF-II for stimulating cell proliferation in cultured
human cells has revealed that higher concentrations of IGF-II are required to produce a
response equivalent to that produced with IGF-I, suggesting that majority of responses to
the IGFs are mediated through the IGF-I receptor rather than the IGF-II receptor (Redder
et al., 1990). A monoclonal antibody (aIR-3) against the IGF-I receptor blocks either
IGF-I-stimulated or IGF-II-stimulated [3H]-thymidine incorporation into DNA in human
fibroblasts in culture (Flier et al., 1986; Van-Wyk et al., 1985). These results indicate that
both IGF-I and IGF-II can act through the IGF-I receptor to stimulate DNA synthesis. In
constrast, Mohan et al. (1991) found that the aIR-3 antibody did not block IGF-II
stimulated proliferation in mouse osteoblasts, MC3T3. Nishimoto et al. (1987b) reported
that in BALB/c 3T3 cells, pertussis toxin inhibited the stimulation of [3H]-thymidine
incorporation by IGF-I and Ca2+ influx, suggesting involvement of a G protein in the
response to IGF-I. Nishimoto et al. (1989) found that the type II receptor interacts with
a G{ protein. The IGF-I receptor is expressed in many cell types and activation by its
ligands is a step required for proliferation (Baserga, 1992). The expression and binding
affinity of two receptors can be regulated by local and systemic factors, such as insulin and
IGFs. For example, in mouse muscle cells, the addition of IGF-II results in
down-regulation of IGF-I receptor mRNA abundance and decreased IGF-I receptor
biosynthesis (Rosenthal et al., 1991).
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(2) Type II IGF receptor
The type II IGF receptor binds IGF-II with a 100 fold higher affinity than IGF-I and
does not bind to insulin (Czech et al, 1989). The type II IGF receptor is distinct from the
type I and insulin receptor in that it consists of a single polypeptide chain (-220 kDa) and
is structurally identical to the mannose-6-phosphate (Man-6-P) receptor (Oshima et al.,
1988) which recognizes mannose-6-phosphate residues on acid hydrolases and targets
these enzymes to the lysosomes (Lobel et al., 1988). The Man-6-P receptor purified with
a lysosomal emzyme affinity column bound to IGF-II with high affinity (Tong et al.,
1988). Conversely, IGF-II receptor purified with an IGF-II affinity column bound to the
lysosomal enzyme and was eluted by mannose-6-phosphate (Roth et al., 1987). These
results strongly suggest that the same receptor binds two different classes of ligands. The
receptor does not have intrinsic kinase activity but can be phosphorylated (Kasuga et al.,
1981; Morgan et al., 1987). Upon IGF-II binding, the type II receptor was found to
interact with a Gj protein to elicit signal transduction within the cell (Nishimoto et al.,
1989).
The IGF-II/Man-6-P receptor is a transmembrane glycoprotein. Evidence indicates
that N-linked glycosylation is required for proper folding of the protein portion of the
receptor and the carbohydrate can be removed without adversely affecting the IGF-II
binding function (MacDonald et al., 1985). Treatment of cells with insulin increases the
cell surface IGF-II receptor number by causing a shift in receptors from a large
intracellular pool to the cell surface in adipocytes (King et al, 1982). The IGF-II/Man-6-P
receptor cycles continuously between the cell surface and intracellular compartments. The
rate of internalization is not affected by binding of either lysosomal enzymes or IGF-II
(Oka et al., 1985). In cultures of normal rat hepatocytes, IGF-II/Man-6-P receptor
number per cell was inversely related to cell density; sparse cultures exhibited higher
receptor density than dense cultures (Scott et al., 1988). In contrast, three rat hepatoma
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cell lines showed high numbers of receptors that were independent of cell density. The
expression of IGF-II/Man-6-P receptors in various rat tissues is developmentally regulated
and similiar to the developmental pattern of serum IGF-II (Moses et al., 1980) and tissue
IGF-II mRNA expression (Brown et al., 1986), suggesting an important role for IGF-II
and the IGF-II/Man-6-P receptor in fetal growth and development.
Bone cells, including human osteoblast cells contain IGF-II receptors. Antibodies
against the murine type II IGF receptor inhibit the binding of IGF-II to bone cells and
inhibit IGF-II-induced cell proliferation (Mohan et al., 1989). In chick bone cells, the
addition of IGF-II increased cell proliferation even in the presence of maximal doses of
IGF-I. These results indicate that at least part of the mitogenic effect of the IGF-II is
mediated through type II IGF receptors in bone cells (Mohan et al., 1989).

3.

IGFBPs
There is a family of proteins that specifically bind to the IGFs. It has been proposed

that binding to the IGFs increases their stability and modulates their biological activities
(Baxter et al., 1986). The first indication that IGFBPs existed came from the observation
that the IGFs circulate as part of a 150 kDa complex in human plasma. This complex
could be dissociated by acid treatment into an IGF and a 50 kDa IGFBP. The function of
the 150 kDa IGFTGFBP complex in adult human plasma was to prolong the half-life of
the IGFs in the circulation (Nissley et al., 1984). In the 1970s, it was directly
demonstrated that the IGFs in most body fluids and in media conditioned by cultured cells
were complexed to proteins that bound IGF-I and IGF-II (Hintz et al., 1977; Hintz et al.,
1980; Zapf et al., 1975; Megyesi et al., 1975). In the mid 1980s, a powerful technique,
called ligand blotting, was introduced which greatly facilitated the identification of more
IGFBPs (Hossenlopp et al., 1986). To date, six IGFBPs (designated IGFBP-1 through
IGFBP-6) have been purified and characterized from body fluids and from conditioned
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media in different cell lines, including bone (Shimasaki et al., 1991b). cDNA clones and
genomic clones for six IGFBPs have been isolated and characterized (Shimasaki et al.,
1991). The protein sequences determined directly or deduced from cDNA nucleotide
sequence demonstrated that the IGFBPs are a family of closely related proteins. Amino
acid sequences of the N- and C-terminal regions of the six IGFBPs are highly conserved
(Shimasaki et al., 1991). Promoter regions of the human IGFBP-1, -2, -3, -5 and rat
IGFBP-1, -2, -3, -4, -5 and -6 genes have been cloned and partially characterized
(Suwanichkul et al., 1990; Brown et al., 1990; Binkert et al., 1992; Cubbage et al., 1990;
Allander et al., 1994; Zhu et al., 1993). All six IGFBPs are produced by osteoblast-like
cells, depending on the species and the experimental conditions employed, however, HBCs
produce predominantly IGFBP-3, -4, -5 and -6 (Mohan et al., 1993). The binding
affinities of each IGFBP for IGF-I or IGF-II are different. IGFBP-1, -3 and -4 bind to
IGF-I and IGF-II with similiar affinity, and IGFBP-2, -5 and -6 bind to IGF-II with higher
afinity (Martin et al., 1986; Mohan et al., 1989; Redder et al., 1990; Roghani et al., 1991).
(1) IGFBP-1
IGFBP-1 was purified from human amniotic fluid (Drop et al., 1984), placenta (Bohn
et al., 1980), endometrium (Bell et al., 1986), conditioned medium from Hep G2
hepatoma cells (Redder et al., 1990), rat H4-II-E hepatoma cells (Yang et al., 1990) and
rat UMR-106 osteosarcoma cells (Koutsiheris et al., 1992), only MG-63 human
osteosarcoma cells express IGFBP-1 (Campbell et al., 1991). IGFBP-1 cDNA clones
were isolated from libraries established from human decidua, placenta, liver and Hep G2
cells (Redder et al., 1990). The complete amino acid sequence of human IGFBP-1 was
deduced from the cDNA sequence and confirmed by direct sequencing of the purified
IGFBP-1 protein. It was predicted that the human IGFBP-1 was a 25.3 kDa protein with
234 amino acids (Lee et al., 1988; Brinkamn et al., 1988; Luthman et al., 1989).
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Sequence analysis demonstrated that IGFBP-1 contains 18 cysteine residues which are
conserved in IGFBPs 1-5 and are thought to stablize the tertiary structure. A C-terminal
Arg-Gly-Asp (RGD) sequence which is involved in IGFBP-1 binding to the fibronectin
receptor as well as several potential Oglycosylation sites were identified (Julkunen et al.,
1988).
The human IGFBP-1 gene spans 5.2 kb and is located on chromosome 7 (Brinkman
et al., 1988a). The mRNA transcribed from this gene is a single 1.55 kb mRNA transcript
(Alitalo et al., 1989) in human liver (Brewer et al., 1988), Hep G2 hepatoma cells
(Brinkman et al., 1988a) and some breast cancer cells (Clemmons et al., 1990). The
human IGFBP-1 promoter has been well characterized. It contains a TATA sequence, a
CAAT box and a response element for the transcription factor, hepatic nuclear factor 1
(HNF-1) (Suwanichkul et al., 1990). Expression of the IGFBP-1 gene is positively
regulated by cAMP and forskolin and negatively regulated by insulin, glucagon and
dexamethasone (Powell et al., 1991; Suh et al., 1994).
It has been shown that IGFBP-1 inhibits both the basal and IGF-I stimulated growth
of chick cartilage in vitro but does not affect IGF-I induced mitogenesis in chick
osteoblasts (Burch et al, 1990). Of the six IGFBPs, IGFBP-1 is least likely to play a
significant role in human bone cell metabohsm because IGFBP-1 is not expressed in
human bone.
(2) IGFBP-2
IGFBP-2 was purified from rat BRL-3A cells (Knauer et al., 1981), MDBK bovine
kidney cells (Redder et al., 1990), human serum (Zapf et al., 1990) and cultured media of
rat astrocytes (Olson et al., 1991). cDNA clones encoding IGFBP-2 have been isolated
from libraries established from adult rat liver (Margot et al., 1989), rat BRL-3A cells
(Brown et al., 1989), bovine MDBK cells (Upton et al., 1990), human fetal liver (Binkert
et al., 1989), Hep G2 hepatoma cells (Zapf et al., 1990a) and human retina (Agarwal et
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al., 1991). The amino acid sequence of rat and human IGFBP-2 are 80% simihar and the
molecular masses are 29.6 and 31.4 kDa for rat and human, respectively (Brown et al.,
1989; Binkert et al., 1989). Like IGFBP-1, an RGD sequence was found near the
C-terminus of IGFBP-2 and no potential N-glycosylation site was found (Brown et al.,
1989; Margot et al., 1989; Binkert et al., 1989). The human IGFBP-2 gene was located
on chromosome 2 and was 40 kb in length (Agarwal et al., 1991; Ehrenborg et al., 1991).
The mRNA transcribed from the human gene is a single 1.38 kb transcript. IGFBP-2
expression has been detected in adult human brain and liver (Binkert et al., 1989), adult rat
brain, testes, ovary (Margot et al., 1989), newborn rat calvarial cells and rat osteosarcoma
cells. Although TE-85 human osteosarcoma cells express IGFBP-2, other human
osteosarcoma cells and normal human osteoblasts do not (Mohan et al., 1991). Promoter
analysis revealed that human, rat and mouse IGFBP-2 promoters contained three SP1
binding sites (Binkert et al., 1992), but neither a TATA sequence nor a CAAT box was
found (Brown et al. 1990; Binkert et al. 1992).
IGFBP-2 binds to IGF-II with 10 fold higher affinity than to IGF-I (Mottola et al,
1986; Szabo et al., 1988). Recombinant human IGFBP-2 inhibited IGF-I stimulated bone
cell proliferation and bone collagen synthesis in fetal rat calvariae cultures, suggesting that
this IGFBP might interfere with bone remodeling (Feyen et al., 1991). l,25(OH)2D3 and
PTH increased, RA, insulin and dexamethasone decreased and GH had no effect on the
production of IGFBP-2 in rat osteoblast cells (Chen et al., 1991; Schmid et al., 1992;
Feyen et al., 1991; Rosen et al., 1994). These data suggest that IGFBP-2 could play an
important inhibitory role in rat bone cell metabolism, but it is uncertain whether IGFBP-2
functions in human bone cell metabohsm.
(3) IGFBP-3
IGFBP-3 has been purified from multiple sources including human plasma (Martin et
al., 1986), procine serum (Walton et al., 1989), rat serum (Zapf et al., 1988), bovine
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serum (Conover et al., 1990b), procine follicular fluid (Ui et al., 1989) and mouse Swiss
3T3 fibroblasts (Blat et al, 1989a). IGFBP-3 is a N-glycosylated protein with a molecular
mass ranging from 34 kDa to 45 kDa (Zapf et al, 1988; Yang et al., 1989). Human
IGFBP-3 is a 38.5-41.5 kDa acid-stable binding subunit that complexes with an acid-labile
85 kDa subunit and binds IGF-I or IGF-II. The three components form the 150 kDa
complex circulating in human plasma (Baxter et al., 1989). The human (Wood et al.,
1988; Spratt et al., 1990), rat (Albiston et al., 1990), porcine (Shimasaki et al., 1990a) and
bovine (Spratt et al., 1991) IGFBP-3 cDNAs have been cloned and the deduced amino
acid sequence for these proteins are quite similiar. The rat and human sequence
demonstrate the following similarity patterns: 64% in exon 1, 68% in exon 2, 95% in exon
3, and 80% in exon 4 (Rechler, 1993). Mature IGFBP-3 in the four species consists of
264 to 266 amino acid residues containing 18 conserved cycteine residues and three
(human, pig and cow) or four (rat) potential N-glycosylation sites but no RGD sequence
(Tressel et al., 1991).
The human IGFBP-3 gene is located on chromosome 7 and is 8.9 kb in length
(Ehrenborg et al., 1990). The gene encodes a single 2.5 kb mRNA transcript (Wood et
al., 1988). Although IGFBP-3 expression has been observed in human placenta and
osteoblast-like cells, rat liver, kidney, stomach, heart, adrenal, ovary, intestine and rat
calvarial osteoblasts, the highest IGFBP-3 mRNA expression was found in the human
placenta and in rat liver (Lamson et al., 1989a; Shimasaki et al., 1989). The IGFBP-3
promoter has been cloned and contains a TATA box, AP-2 and SP1 sites (Cubbage et al..
1990).
IGFBP-3 can either enhance or inhibit the metabolic or mitogenic effects of the IGFs,
depending on the cell type and the study conditions (Mohan, 1993; De Mellow et al.,
1988). In addition, it may increase the half-life of IGFs by serving as a local reservoir
from which IGFs can be continuously released into the local environment by autocrine or
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paracrine actions (Bautista et al., 1990; Schmid et al, 1989). IGFBP-3 is the predominant
circulating IGFBP in postnatal life (Martin et al., 1992) and can be up-regulated in vivo by
GH and IGF-I (Schmid et al., 1989; Zapf et al., 1989) and down-regulated by IGFBP-3
protease (Suikkari et al., 1991). In vitro studies demonstrated that IGF-I increased
IGFBP-3 secretion in human osteoblasts and fibroblasts (Smith et al., 1990; Martin et al.,
1990). Systemic hormones, growth factors and cytokines, such as TGF-(3 (Nakao et al.,
1994), GH (Schmid et al., 1989), l,25(OH)2D3 (Moriwake et al., 1992; Scharla et al.,
1993), BMP-7 (Knutsen et al., 1995) increased, while dexamethasone (Nakao et al., 1994)
inhibited IGFBP-3 production in human osteoblast-like cells. In rat osteoblasts,
prostaglandin E2, estradiol, thyroid hormone and PTH increased while cortisol inhibited
IGFBP-3 release (Feyen et al., 1991; Schmid et al., 1989; Schmid et al., 1992). Because
major regulators of skeletal development affect IGFBP-3 expression, this IGFBP could
play a significant role in bone metabohsm.
(4) IGFBP-4
IGFBP-4 is a 24 kDa binding protein purified from the conditioned medium of human
osteosarcoma TE89 (Mohan et al., 1989), human prostatic carcinoma PC-3 cells (Perkel
et al., 1990), human colon carcinoma HT-29 cells (Culouscou et al., 1991), human
glioblastoma T-98G cells (Camacho et al., 1992), human fetal skin fibroblasts (Camacho
et al., 1992), rat neuroblastoma B-104 cells (Ceda et al., 1991; Cheung et al., 1991),
human serum (Kiefer et al., 1991b), rat serum (Shimonaka et al., 1989) and ovine plasma
(Walton et al., 1990). IGFBP-4 cDNA clones were isolated from rat fiver (Shimasaki et
al., 1990b), human placenta (Shimasaki et al., 1990b), human osteosarcoma TE89 (La
Tour et al, 1990) and bovine pulmonary artery (Moser et al, 1992) cDNA libraries.
Mature IGFBP-4 contains 233 (rat) or 237 (human) amino acid residues. There are 18
cysteine residues and two additional cysteine residues that are not present in other
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IGFBPs, a potential N-glycosylation site, but no RGD sequence was identified (La Tour et
al., 1990; Shimasaki et al., 1990).
The human IGFBP-4 gene is located on chromosome 17 and spans 15 kb. The gene
encodes a 1.8 or 2.2 kb mRNA transcript (LaTour et al., 1990; Shimasaki et al., 1991;
Camacho et al., 1992). IGFBP-4 expression occurs in human embryonic and adult liver,
brain (Kiefer et al., 1991), untransformed osteoblasts, osteosarcoma TE85 and TE89 cells
(La Tour et al., 1990) as well as in rat liver, adrenal, testes, spleen, heart, lung, kidney,
stomach, hypothalamus and brain (Shimasaki et al., 1990a).
The function of IGFBP-4 is inhibitory. Human IGFBP-4 was found to inhibit both
basal and IGF-mediated chick pelvic cartilage growth (Schiltz et al, 1993). It also
inhibited the binding of IGF-II to the type II IGF receptor (Perkel et al., 1990) and cell
proliferation (Amamani et al., 1993) in MC3T3 mouse osteoblasts. It has been reported
that the levels of IGFBP-4 inversely correlated with the bone cell proliferation rate
(Mohan et al., 1991) and antisense oligo to IGFBP-4 mRNA stimulated bone cell
proliferation (Maple et al., 1992). Therefore, IGFBP-4 is a potent bone cell proliferation
inhibitor.
The regulation of IGFBP-4 in osteoblasts and other cell types has been studied in
vitro and in vivo. In cultured human osteoblasts, agents which inhibit cell proliferation,
such as PTH, cAMP, l,25(OH)2D3 increase IGFBP-4 expression, whereas agents which
enhance cell proliferation, such as IGF-I, IGF-II, progesterone, BMP-7 decrease IGFBP-4
expression indicating an inverse relationship between IGFBP-4 production and
proliferation (Scharla et al., 1991; La Tour et al., 1990; Mohan, 1993). In clonal mouse
osteoblasts, the addition of l,25(OH)2D3, an osteoblast differentiation and
antiproliferation agent, increased IGFBP-4 expression and decreased [3H] thymidine
incorporation (Scharla et al., 1991), suggesting that increased IGFBP-4 not only inhibited
the proliferative effect of IGF-I but also initiated a switch in osteoblast phenotype.
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Importantly, changes in circulating IGFBP-4 levels may reflect changes in bone
metabohsm. It has been reported that IGFBP-4 levels are higher in elderly women with
hip fractures (Rosen et al, 1992) and in patients with a chronic exposure to high oral
doses of l,25(OH)2D3(Scharla et al, 1993). Therefore, it can be concluded from the
above observations that IGFBP-4 is an important inhibitory component of the IGF system
in osteoblast cell metabohsm.
(5) IGFBP-5
IGFBP-5 is a 29 kDa binding protein that was purified from adult rat serum
(Shimasaki et al., 1991b), human bone (Bautista et al., 1991), cerebrospinal fluid (Binoux
et al., 1991a) and glioblastoma T98G cells (Camacho et al., 1992). It is predicted that
mature rat and human IGFBP-5 contains 252 amino acid residues and shares 97% amino
acid sequence identity. IGFBP-5 cDNA clones were isolated from human placenta
(Shimasaki et al., 1991b), osteosarcoma (Kiefer et al., 1991a) and rat ovary cDNA
libraries (Shimasaki et al., 1991b). Both rat and human IGFBP-5 contain 18 conserved
cysteine residuesand lack RGD sequences and N-glycosylation sites (Rechler, 1993). The
human IGFBP-5 gene was located on human chromosome 2 (Shimasaki et al., 1991b) and
its promoter contains a TATA element (Allander et al., 1994), a CAAT box, AP-2
concensus sequences, putative PRE/GRE sequences and a putative RARE sequence
(Boonyaratanakomkit et al., 1994).
The human and rat IGFBP-5 genes encode multiple transcripts between 5 to 6 kb.
Expression is found in multiple tissues, including kidney, lung, heart, adreal, stomach and
intestine (Shimasaki et al., 1991). Cultured osteoblasts from human, rat and mouse also
express IGFBP-5 which can be regulated by growth factors and systemic hormones
(Rosen et al., 1994). For example, IGFBP-5 expression was increased by PTH and other
cAMP analogs in UMR-106-01 rat osteosarcoma cells (Conover et al., 1993). In human
osteoblast cells, IGFBP-5 expression was inhibited by dexamethasone (Chevalley et al.,
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1993) and increased by progesterone (Lempert et al., 1992; Boonyaratanakomkit et al.,
1994). IGF-I, IGF-H (Lempert et al., 1992) and BMP-7 (Knutsen et al., 1995) increased
IGFBP-5 mRNA expression in SaOS-2 cells.
IGFBP-5 binds with higher affinity to IGF-II than IGF-I. Among the six IGFBPs,
IGFBP-5 is unique in that it consistently stimulates IGF-I and IGF-II actions (Mohan et
al., 1993). IGF-I and IGF-II do not bind to the bone matrix directly. IGFBP-5 has an
hydroxyapatite binding site so that it not only binds to IGF-I and IGF-II, but also to
hydroxyapatite, and thus fixes IGF-II and IGF-I to the mineralized bone matrix. The
delayed paracrine actions of the IGFs are thought to result from a release of the bound
IGFs from the bone matrix (Bautista et al., 1991; Mohan, 1993). Because IGFBP-5
stimulates cell growth in osteoblast cells (Andress et al., 1992), IGFBP-5 is an important
stimulatory regulator of bone metabohsm.
(6) IGFBP-6
IGFBP-6 was purified from normal and transformed human lung fibroblasts (Martin et
al., 1990; Forbes et al., 1990), human cerebrospinal fluid (CSF) (Roghani et al., 1991),
porcine follicular fluid (Shimasaki et al., 1991a), human serum (Zapf et al., 1990), rat
serum (Shimasaki et al., 1991b) and human osteosarcoma U2-OS cells (Andress et al.,
1991). The apparent molecular mass ranged from 32-34 kDa from fibroblasts (Martin et
al., 1991), 30-32 kDa from CSF (Roghani et al., 1991) and 28-30 kDa from human serum
(Zapf et al., 1990). IGFBP-6 cDNA was isolated from rat and human placenta cDNA
libraries (Shimasaki et al., 1991a) and from a human osteosarcoma library (Kiefer et al.,
1991b). Mature rat and human IGFBP-6 contain 201 and 206 amino acid residues with
predicted molecular masses of 21.5 kDa and 22.8 kDa, respectively (Redder, 1993). The
difference between the apparent molecular mass of human IGFBP-6 (28-34 kDa) and the
predicted molecular mass reflects the presence of glycosylation. The monosaccharide
composition of IGFBP-6 suggested the presence of O-linked ohgosaccharide chains.
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Approximately 20% of the mass of native human IGFBP-6 consists of O-linked
ohgosaccharide chains (Bach et al., 1992). Human IGFBP-6 lacks two and rat IGFBP-6
lacks 4 of the 18 conserved cysteines found in IGFBPs 1-5, respectively. Human
IGFBP-6 does not contain an RGD sequence (Shimasaki et al., 1991).
The rat IGFBP-6 gene was cloned from a rat genomic library (Zhu et al., 1993). The
gene spans 5.1 kb and contains four exons and three introns. The promoter region of the
rat IGFBP-6 gene lacks a TATA box or CAAT box consensus sequence but contains
putative czs-regulatory elements, including an SP1 binding site, an estrogen response
element (ERE) and a putative RA reponse element (RARE) (Zhu et al., 1993). The
human IGFBP-6 gene was located on chromosome 12 by somatic cell hybridization
(Shimasaki et al., 1991a) but the gene and promoter of human IGFBP-6 have not yet been
isolated or characterized.
IGFBP-6 mRNA is expressed in human breast cancer cells (Sheikh et al., 1993),
transformed and untransformed fibroblast cells (Martin et al., 1994), human adult liver,
human osteosarcoma cells and human brain (Kiefer et al., 1991a). The expression of
IGFBP-6 is increased by TGF-(3 and agents that increase intracellular cAMP
concentrations, including dibutyryl cAMP, forskolin, isobutylmethylxanthine and cholera
toxin in human fibroblast cells (Martin et al., 1994). In estrogen receptor-negative human
breast cancer cells, the IGFBP-6 protein level was increased by RA (Sheikh et al., 1993).
A distinguishing characteristic of IGFBP-6 is its 20 to 100 fold preferential affinity for
IGF-II over that for IGF-I (Martin et al., 1990; Forbes et al., 1990; Roghani et al., 1991;
Bach et al., 1992; Bach et al., 1993), suggesting that IGFBP-6 has a special role in
modulating IGF-II actions. It was reported that recombinant human IGFBP-6 expressed
in yeast inhibited IGF-II-stimulated DNA synthesis and glycogen synthesis completely, but
inhibited the stimulation by IGF-I to only a minor extent (Kiefer et al., 1992). Recent
studies demonstrated that rhIGFBP-6 specifically inhibited IGF-II-induced rat myoblast
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L6A1 cell differentiation, but had no effect on IGF-I-induced differentiation (Bach et al.,
1994). The regulation and action of IGFBP-6 in skeletal tissue remains to be defined.

C. Effects of l,25(OH)2D3 and RA on the IGF System
RA and l,25(OH)2D3 are similiar hormones in that they affect cell proliferation and
differentiation and recruit growth factor-mediated effects. The effect of l,25(OH)2D3 on
human bone metabolism has been studied. The effects of RA on HBCs are unknown.

1.

Effects of l,25(OH)2D3on the IGF system
l,25(OH)2D3 regulates expression of IGF system components in murine and human

osteoblast cells and the effects are species dependent. In cultured neonatal mouse
calvaria, l,25(OH)2D3 stimulated the release of IGF-II but inhibited the release of IGF-I
(Linkhart et al., 1991). In rat osteosarcoma UMR-106 cells and in short-term cultures of
HBCs, l,25(OH)2D3 stimulates production and secretion of IGF-I (Chen et al., 1991;
Chenu et al., 1990). In rat osteoblast-like cell cultures, l,25(OH)2D3increases the
secretion of inhibitory IGFBP-2 (Chen et al., 1991) even though the physiological
consequence of this action has not yet been defined. In clonal mouse MC3T3-E1
osteoblasts, addition of l,25(OH)2D3 increased the release of inhibitory IGFBP-4 with a
concurrent decrease in [3H] thymidine incorporation (Scharla et al., 1991). These studies
clearly demonstrated a correlation between increased inhibitory IGFBP expression and
decreased cell proliferation and suggested that the action of l,25(OH)2D3 on murine
osteoblast cell proliferation was at least in part mediated by IGF system components. In
cultured human osteoblast cells, 1,25(OH)2D3 increased IGFBP-4 secretion and decreased
[3H] thymidine incorporation (Scharla et al, 1993). It was also found that l,25(OH)2D3
stimulated IGF-I production (Chenu et al., 1990), collagen synthesis (Franceschi et al.,
1988), ALP activity (Kyeyune-Nyombi et al., 1991) and osteocalcin secretion (Wergedal
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et al., 1992) in human osteoblast cells, suggesting that l,25(OH)2D3 also acts on human
osteoblast cell proliferation and differentiation by recruiting the IGF system. In patients
receiving large doses of l,25(OH)2D3(2-3 pg/day), the serum IGF-I concentration fell by
50% while inhibitory IGFBP-4 increased by 70% (Scharla et al., 1993).

2.

Effects of RA on the IGF system
There are few studies of the effect of RA on human or murine osteoblast systems.

Several lines of evidence using human breast cancer cells, human fibroblasts and rat
osteoblasts have suggested that RA affects the IGF system. It was found that estrogen
receptor (ER)-positive cells predominantly synthesized IGFBP-2, -4 and -5 whereas
ER-negative cells produced IGFBP-3, -4 and -6 (Sheikh et al., 1992; Clemmons et al.,
1990). In two ER-negative human breast cancer cell lines, MDA-MB-231 and
MDA-MB-468, 10-6 M RA increased the expression of IGFBP-3 and -6, but not IGFBP-4
(Sheikh et al., 1993a). However, in the ER-positive human breast cancer cell lines,
MCF-7, RRO-I, ZR-75 and T47D, 10-6 M RA increased IGFBP-4 gene expression (Sheikh
et al., 1993b; Adamo et al., 1992), suggesting that RA mediated changes in IGFBP-4
mRNA expression in human breast cancer cells requires a functional ER. In cultured
MCF-7 cells, RA increased inhibitory IGFBP-2, -3 and -4 protein levels in the CM and
blocked IGF-I stimulated cell proliferation. The change in proliferation rate was not
associated with a significant change in specific IGF-I binding sites on the MCF-7 cells
(Fontana et al., 1991). IGFBP-5 mRNA levels in T47D human breast cancer cells were
decreased by RA (Shemer et al., 1993). These findings support the hypothesis that RA
inhibits the growth of breast carcinoma cells by increasing the secretion of inhibitory
IGFBPs, which could directly reduce IGF bioactivity leading to growth inhibition.
Regulation of IGFBP expression by RA was also reported in other cell types. In human
transformed and untransformed fibroblast cells, IGFBP-6 secretion was increased 3 fold
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by 10-6 M RA (Martin et al., 1994). In human transformed cervical epithelial cells, RA
increased IGFBP-3 gene expression and inhibited IGF-I stimulated cell proliferation
(Leyen et al., 1994). Although RA has been shown to influence the various components
of the IGF system in a number of cell types, very little is known on RA effects on the IGF
system in bone cells.

D. Objectives
As discussed in the introduction, developmental studies describing the effect of RA on
embryogenesis and skeletal metabolism have been done in rodent model systems. These
studies indicate that RA regulates osteoblast cell proliferation and differentiation,
however, the studies are contradictory and depend on osteoblast cell developmental stages
and on cell culture conditions. Although RA has been shown to play a very important role
in regulating osteoblast cell proliferation and differentiation using mouse and rat bone
cells, very little is known on the effects of RA on HBC proliferation and differentiation.
Studies of the effect of RA on IGF system components are preliminary and also have used
only murine osteoblast models. One recent study reported that d\\-trans RA decreases
IGFBP-2 (an inhibitory IGFBP) expression in rat osteoblast cultures (Schmid et al., 1992),
but the effect of RA on proliferation and differentiation in these cells was not studied.
There are many examples showing that the effect of osteoregulatory agents such as PTH,
l,25(OH)2D3 and cAMP on expression of IGF system components is clearly different in
murine and human osteoblast models (Scharla et al., 1993; Rosen et al., 1994). The
findings using rodent models cannot be extrapolated to human models since a number of
studies have shown that the responsiveness of rat and human bone cells to a variety of
systemic and local effectors are different. Because RA has been widely used in cancer
chemotherapy, it is important to determine its skeletal side effects as well as the
mechanism(s) by which RA mediates these effects. Therefore the goals of my dissertation
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were 1) to determine the effect of RA on human osteoblast cell proliferation and
differentiation, 2) to determine if RA recruited the IGF system to mediate its effects and 3)
to determine the molecular mechanisms altering expression of IGFBP-6, an IGF system
component that was most significantly affected by RA treatment.
In this dissertation, two human osteoblast-like cell strains were utilized, the human
osteoblast-like SaOS-2 osteosarcoma cell model and primary human osteoblast-like cells
derived from skull fragments. I found that RA inhibited proliferation and differentiation of
both the transformed and untransformed human osteoblast cells. Both models were
thereafter used to survey the response of IGF system components to RA at the protein and
mRNA level and to determine the molecular mechanisms contributing to these responses.

CHAPTER TWO
H. MATERIALS AND METHODS
A. Materials
1.

Cells
The human osteoblast-like osteosarcoma cell strains, SaOS-2 (ATCC #HTB85) and

U2-OS (ATCC #HBT96) were purchased from the American Type Culture Collection
(Rockville, MD). An SaOS-2 cell population that exhibited low alkaline phosphatase
activity was isolated in our laboratory (Farley et al., 1991). Normal human bone cell
cultures were established from skull fragments obtained from a 27 year old female by
outgrowth of cells from explants as described previously (Linkhart et al., 1991). Normal
human skin fibroblast cell cultures were established from outgrowth of skin explants
obtained from a 25 year old female. Human skull and skin samples were obtained at
autopsy by the NCI Cooperative Human Tissue Network (Birmingham, AL) and
immediately shipped on ice for experimental use.

2.

Reagents
Dulbecco's modified Eagle medium (DMEM) was obtained from GLBCO (Santa

Clara, CA). Bacto-yeast extract and Bacto-tryptone were obtained from DIFCO (Detroit,
MI). Fe supplemented calf serum was purchased from Hyclone (Logan, UT). Bovine
Serum Albumin (BSA) and 5,6-dichloro-l-P-D-ribofiiranosyl benzimidine (DRB) were
obtained from Calbiochem Corp. (La Jolla, CA). Guanidinium isothiocyanate was
obtained from Fluka Chemicals (Ronkonoma, NY). Acrylamide, bis-acrylamide and
Bradford-dye reagent were purchased from Bio-Rad Laboratories (Richmond, CA).
l,25(OH)2D3 was provided by Dr. Millan R. Uskokovic of Hoffman-La Roche Inc.
(Nutley, NJ). AW-trans retinoic acid, polyethylene glycol (8000), cycloheximide,
chloramine T and p-nitrophenyl phosphate were purchased from Sigma Chemical
43
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Company (St. Louis, MO). SeaPlaque agarose was purchased from FMC BioProducts
(Rockland, ME). Agarose NDO was obtained from National Diagnostics (Altlanta, GA).
RNase-free DNase I was obtained from GIBCO/BRL-Life Technologies Inc.
(Gaithersburg, MD). Other molecular biology reagents were obtained from Sigma
Chemical Company (St. Louis, MO), USB (Cleveland, OH) and Fisher Scientific (Tustin,
CA). Na[125I] and [3H]-thymidine were purchased from International Chemical and
Nuclear Company (Irvine, CA). a-[32P]-dCTP (3,000 Ci/mmol) and y-[32P]-ATP (7,000
Ci/mmol) were purchased from ICN Biomedicals Inc. (Costa Mesa, CA).
The human IGFBP-3 (Wood et al., 1988) and IGFBP-6 (Shimasaki et al., 1991)
cDNA plasmids were provided by Dr. Shimasaki (La Jolla, CA). The human IGFBP-4
cDNA was cloned in our laboratory (LaTour et al, 1990). The human IGFBP-5 cDNA
was provided by Dr. Dony (Boehringer Mannheim, Penzberg, Germany). This probe was
derived by RT-PCR amplification of the full length coding region of IGFBP-5 mRNA.
IGF-II (ATCC #57482), vitamin D receptor (VDR) (ATCC #61260), IGF-I receptor
(ATCC #59294) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (ATCC
#57090) cDNA probes were purchased from ATCC (Rockville, MD). The human type I
procollagen cDNA probe (Myers et al., 1981) was provided by Dr. Francesco Ramirez
(Brooklyn, NY). The human osteocalcin cDNA probe (Celeste et al., 1986) was obtained
from Dr. John M. Wozney (Cambridge, MA). Oligo probes were synthesized by the
Loma Linda University, Center for Gene Therapy (Loma Linda, CA). The Klenow
fragment of DNA Polymerase I was from Pharmacia (Piscataway, NJ) or Promega
(Madison, WI). Superscript™ II Reverse Transcriptase was obtained from GIBCO/BRL
Life Technologies Inc. (Gaithersburg, MD). Vent (exo ) DNA Polymerase was from New
England Biolabs Inc. (Beverly, MA). T4 Polynucleotide Kinase, RNasin, restriction
enzymes and buffers were from Promega (Madison, WI) and GIBCO/BRL Life
Technologies Inc. (Gaithersburg, MD).
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Recombinant human IGF-I was purchased from Amgen (Thousand Oaks, CA).
Human recombinant IGF-II was purchased from Bachem Inc. (Torrance, CA).
Nonglycosylated human recombinant IGFBP-3 and rabbit anti-human IGFBP-3 polyclonal
antibodies were kindly donated by Dr. A. Sommer (Cletrix Pharmaceuticals, Santa Clara,
CA) and Dr. V. Makku (Genentech. Inc., San Francisco, CA), respectively. Human
recombinant IGFBP-5 was a gift from Dr. C. Dony and Dr. Kurt Lang (Boehringer
Mannheim, Penzberg, Germany). Guinea pig anti-human IGFBP-5 antiserum was
developed in our laboratory. Goat anti-rabbit IgG and normal rabbit serum were provided
by Pel-Freez Biologicals (Roger, AK).

3.

Miscellaneous Materials
MagnaGraph nitrocellulose membrane was purchased from Micro Separations Inc.

(Westborough, MA). Nytran nylon membrane was purchased from Schleicher & Schuell
Inc. (Keene, NH). ART tips were purchased from Molecular Bio-Products Inc. (San
Diego, CA). 10-20% gradient acrylamide SDS gels were purchased from JULE Inc.
(New Haven, CT). dNTPs and dN6 (hexanucleotides) were obtained from Pharmacia
(Piscataway, NJ). NACS PrePAC™ columns were obtained from GIBCO/BRL-Life
Technologies Inc. (Gaithersburg, MD). MERmaid kits were purchased from BIO 101
Inc. (La Jolla, CA). Wizard ™ Miniprep DNA Purification columns were obtained from
Promega (Madison, WI). Qiagen Plasmid Maxi kits were purchased from Qiagen Inc.
(Chatsworth, CA). Culture dishes and polypropylene tubes were obtained from Coming
Glass Works (Coming, NY). Multi-well plates were from Costar (Cambridge, MA).
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B. Methods
1.

Cell Culture
In preparation for RA addition, cells were plated at 7,500 cells/cm2 and incubated in

DMEM supplemented with 10% calf serum (CS) at 37°C. A retinoic acid stock solution
of 10'2 M was prepared in dimethyl sulfoxide (DMSO) and 1 ml aliquots were stored at
-80°C. Further dilutions of RA were made using DMEM supplemented with 0.1% BSA
immediately before addition to cultures. When cells were 70-80% confluent, the medium
was replaced with serum-free DMEM supplemented with 0.1% BSA. After 24 h, the
medium was removed and fresh serum-free DMEM with 0.1% BSA containing RA
(lO ^-lO^M) or vehicle (DMSO at concentrations equivalent to that found with RA
treatment) was added. Cells were harvested and RNA was extracted at different times
after incubation with effectors. After 48 h of RA treatment, the conditioned media was
collected into BSA-precoated tubes to decrease non-specific binding of IGFBPs to the
plastic tube surfaces.

2.

Cell Proliferation Assay
The cell proliferation assay was conducted as described ( Nakao et al., 1994). For the

cell proliferation assay, cells were plated into 6 cm diameter culture plates at 50,000
cells/plate in DMEM with 10% CS and incubated for 24 h. After 24 h of adaptation in
serum-free DMEM with 0.1% BSA, cells were treated with CS (5%), RA (lO^M),
vehicle or a combination of the above effectors for the indicated times. Cells were
suspended with 0.05% Trypsin and 0.02% EDTA solution and the number of cells on each
plate was counted with a hemocytometer under a phase contrast microscope (Leitz,
Wetzlar, Germany).
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3.

ALP Activity Assay
The ALP activity assay was prepared as previously described (Kyeyune-Nyombi et

al, 1991). Cells were plated into 24-web plates in DMEM with 10% CS at 2 x 104
cebs/ml/web. The l,25(OH)2D3 was dissolved in absolute ethanol at 10-4 M and aliquots
were stored at -80°C. After 24 h of adaptation in serum-free DMEM with 0.1% BSA,
cebs were treated with vehicle or RA (lO ^-lO^M) with or without l,25(OH)2D3 (10-8M)
for 48 h. The medium was removed and the cebs were rinsed twice with PBS.
Subsequently, 200 pi of 0.03% Triton X-100 was added to each web and cebs were
scraped and then incubated at room temperature with shaking for 1 h. The ALP enzyme
activity in the extracts was determined by measuring the rate of hydrolysis of
p-nitrophenyl phosphate to p-nitrophenol according to Kyeyune-Nyombi et al. (1991).
ALP reaction mixture (200 pi ) was added into a web of a 96-web plate. The reaction
was initiated by the addition of 25 to 50 pi of ceb extract to each web and the plates were
incubated at room temperature for 30 min to 16 h. The absorbance was read at 410 nm
The protein concentrations of the ceb extract were determined using the Bradford dye
binding method with BSA as a standard as described in the product's manual. Briefly,
increasing amounts of BSA (0.1 to 5 pg in 100 pi of water) or 20 pi of sample was added
to water to a final volume of 100 pi in a web of a 96-web plate. 100 pi of 40% Bradford
dye solution was then added to each web and the plates were incubated at room
temperature for 5 to 10 min. The absorbance of the solution was measured at 550 nm
using a automated plate reader (SLT, Lablnstruments, Austria). A standard curve was
prepared from the BSA standard and used to estimate the protein concentration in the
unknown samples. ALP activity was calculated as mibiunits per mibigram of protein, and
the results were reported as percentage of control (the percentage of the ratio of the
specific activity of ALP in the effect or-treated cebs to that in the vehicle-treated cebs).
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4.

Labeling and Separation of Labeled Proteins from Free Iodine
IGF-I, IGF-II, IGFBP-3 and IGFBP-5 were iodinated by a modification of the

chloramine T method (Mohan et al., 1990). One (ig of protein in 20 pi of 10 mM acetic
acid was incubated with 1 mCi of Na[125I] and 20 pi of chloramine T solution for 45
seconds. The reaction was terminated by the addition of 200 pi of 10 mM sodium
phosphate buffer (pH 7.5) containing 0.25% BSA and 1% potassium iodide. The
iodinated protein was purified using a C18Sep-Pak cartridge. The cartridge was primed
with 5 ml of 95% acetonitrile containing 0.1% trifluoroacetic acid (TFA) and then loaded
with the iodination reaction mix. The unbound Na[125I] was removed from the cartridge
by washing with 0.1% TFA in water. The iodinated protein was eluted with 50%
acetonitrile containing 0.1% TFA. The specific radioactivity of the labeled protein was
determined by liquid scintillation counting. Aliquots of the labeled proteins were stored at
-70°C.

5. IGF Competitive Binding Assay
To carry out the IGF binding assay, human IGF-I and IGF-II were used as tracer and
standard as described (Mohan et al., 1990). HBCs were plated into 24-well plates in
DMEM with 10% CS at 2 x 104 cells/well. After 24 h of adaptation to serum-free
DMEM with 0.1% BSA, the cells were treated with RA (lO^M), l,25(OH)2D3 (10-8M),
RA (lO^M) and l,25(OH)2D3 (10-8M) or vehicle for 48 h. The cells were rinsed with 1
ml of IGF binding buffer to remove loose and non-adherent cells. 200 pi of IGF binding
buffer, 50 pi of [125I]-labeled-IGF-I or [125I]-labeled-IGF-II (200,000 cpm/ml) and 50 pi
of IGF-I or IGF-II standard (0.2-25.6 ng/well) were added to cells. After 1.5 h of
incubation at room temperature, the radioactive medium was removed and the cells were
rinsed five times with this binding buffer. The cells were treated with 2 ml of IGF lysis
buffer and the amount of [125I]-IGF-I or [125I]-IGF-II bound to the cells in each well was
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determined by counting the cell lysate in a Micromedic Automatic Gamma Counter
(Alabama). Displacements of [125I]-IGF-I or [125I]-IGF-II by various concentrations of
cold IGF-I or IGF-II standard were plotted. The curve was used to determine the IGF-I
or IGF-n binding affinity and capacity to the cell surface. The sensitivity of this assay was
4 to 12 ng/ml.

6.

IGFBP-5 Radioimmunoassay (RIA)
The IGFBP-5 RIA was developed as previously described (Mohan et al., 1995).

Briefly, a diluted guinea pig anti-human recombinant IGFBP-5 antiserum (1:1,000) was
used as the primary antibody. Diluted goat anti-guinea pig antiserum (1:20) was used as
the secondary antibody. Recombinant human IGFBP-5 was used as the standard and
tracer. The RIA buffer was used for all dilutions and additions. Experimental samples or
a series of diluted human recombinant IGFBP-5 (0-500 ng/ml) (100 pi) were incubated
with 200 pi of RIA buffer and 100 pi of diluted rabbit anti-human IGFBP-5 antiserum
(1:1,000) at room temperature for 1 h. Then 40,000 cpm [125I]-labeled IGFBP-5 tracer in
100 pi of RIA buffer was added to each tube and incubated at 4°C overnight. The
antigen-antibody complexes were precipitated with 500 pi of diluted goat anti-guinea pig
serum (1:20) and 200 pi of 8% PEG-8000 after incubating at room temperature for 3-4 h.
The supernatants were removed after centrifugation at 1,300 x g for 30 min and the
radioactive precipitates were collected and quantitated by hquid scintillation counting.
There is no significant cross-reactivity with other known IGFBPs at up to 1 pg/ml
concentrations.
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7.

Western Ligand Blot
(1) Amicon nitration of conditioned medium
CM (10 ml) was placed in an Amicon ultrafiltration cell with a YM 10 membrane.

Proteins with molecular weights below 10 kDa were not retained, while IGFBPs and other
proteins with molecular weights greater than 10 kDa are retained in the Amicon cell. The
CM was concentrated approximately 20 fold and then 50 ml of 1 M acetic acid was added
and the proteins were reconcentrated to about 1 ml. The concentrated CM was dried in a
SpeedVac concentrator (Savant, Farmingdale, NY) and the dried residues were
redissolved in 500 pi of 1 x ligand blot sample buJffer and was heated at 65°C for 3 min to
denature the proteins before loading on an SDS-polyacrylamide gel.
(2) SDS-Polyacrylamide gel electrophoresis (PAGE) and western transfer
Western ligand blot analysis was carried out according to Hossenlopp (1986). The
resolving gel used was a precast gradient gel containing 10-20% acrylamide with 0.1%
SDS. A 3% polyacrylamide stacking gel overlaying the gradient gel was prepared. The
samples were prepared as described above and were loaded onto the stacking gel.
Electrophoresis was carried out at room temperature in running buffer at 10 mA
overnight. After electrophoresis, the gel was fixed with 20% methanol in transfer buffer
for 15 min at room remperature. The size fractionated proteins were electroblotted at 50
volts for 3.5 h onto a MSI nitrocellulose membrane with transfer buffer at 4°C.
(3) Ligand blot analysis
The MSI nitrocellulose membrane containing size fractionated proteins was incubated
at 4°C in 100 ml of a washing solution for 30 min and then changed to 100 ml of a
blocking solution and incubated at 4°C for 2 h. It was further incubated in 100 ml of
hybridization solution at 4°C for 10 min. Hybridization was carried out in 10 ml of
hybridization solution containing [125I]-labeled IGF-II (106 cpm/ml) at 4°C for 16 to 24 h
with shaking. The membrane was washed three times with 100 ml of washing solution for
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15 min each at room temperature. Autoradiography was performed at -70°C for 1 to 2
weeks.

8.

Plasmid Preparation
A single bacteria colony from an LB plate (1.5% agar in LB broth with appropriate

antibiotic) was inoculated into 10 ml of LB broth containing either ampicillin (100 pg/ml)
or tetracycline (20 (ig/ml) and was grown overnight at 37°C with shaking. Bacteria
suspension (10 ml) was then added to 10 to 500 ml of fresh LB containing the antibiotic
and was incubated at 37°C overnight with vigorous shaking. The bacteria were pelleted
by centrifugation at 5,000 x g for 15 min at 4°C in a 250 ml polypropylene bottle (100 to
500 ml) or 50 ml disposable tube (10 to 50 ml) in a Sorvall RC-2B centrifuge (Du Pont,
Newtown, CT). Plasmid DNA was recovered using an alkalysis, phenol extraction
method or with Wizard mini-Prep or Qiagen kits.
(1) Alkali lysis preparation
Plasmid DNA for cDNA probe preparation was prepared as described by Titus
(1992). Briefly, 100 ml of bacteria culture was pelleted by centrifugation, resuspended in
5 ml of TENS buffer and shaken until sticky. 2.5 ml of 3.0 M sodium acetate, pH 5.2 was
added and shaken until the lysate cleared. The cell lysate was centrifuged at 10,000 x g
for 20 min at 4°C and the supernatant was treated with RNase A (10 fig/ml) at room
temperature for 10 min. 10 ml of 0.1 M Tris-HCl (pH 8.0)-saturated
phenol/chloroform/IAA (24:24:1) was added to the supernatant and the mixture was
shaken and placed on ice for 5 min. The mixture was centrifuged as described above. The
supernatant was removed and 1/10 volume of 3 M sodium acetate (pH 5.2) and 2 volumes
of absolute ethanol (-20°C) was added to the upper aqueous phase. The solution was
mixed and placed on crushed dry ice for at least 1 h to precipitate the DNA. Plasmid
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DNA was collected by centrifugation at 10,000 x g for 15 min at 4°C. The pellet was
washed with 70% ethanol and resuspended in sterile deionized water. The yield was 2
pg/ml bacterial culture.
(2) Wizard mini-preparation
To check for the presence of the appropriate plasmid within a given colony, a small
scale (<10 ml) plasmid DNA preparation was carried out using the Wizard mini
preparation kit according to manufacturer’s protocol. Four ml of a saturated culture of
bacteria were pelleted by centrifugation and resuspended in 200 pi of cell suspension
solution (50 mM Tris-HCl, pH 7.5, 10 mM EDTA and 100 pg/ml RNase A). 200 pi of
the cell lysis solution (0.2 M NaOH, 1% SDS) was added and mixed to lyse the cells. 200
pi of neutralization solution (2.55 M potassium acetate, pH 4.8) was added and mixed.
The cell lysate was spun at 14,000 x g for 5 min and the supernatant was collected. One
ml of DNA purification resin was added to the supernatant and loaded onto a mini-column
provided with the kit. The mixture was pulled through the mini-column by applying a
vaccum. The column was washed by the addition of 2 ml column wash solution ( 200 mM
NaCl, 20 mM Tris-HCl, pH 7.5, 5 mM EDTA) and the plasmid DNA was eluted with 50
pi of water preheated to 65°C. The yield was about 1-2 pg DNA/ml bacterial culture.
(3) Qiagen maxi-preparation
For large amounts of plasmid DNA (>100 pg), the Qiagen plasmid preparation kit
was employed according to the manufacturer's protocol. Bacterial cells were collected by
centrifuging 500 ml of bacteria at 5,000 x g for 10 min at 4°C. The bacteria pellet was
resuspended in 10 ml of PI buffer (50 mM Tris-HCl, pH 8.0, 10 mM EDTA and 100
pg/ml RNase A) and 10 ml of freshly prepared P2 buffer (200 mM NaOH and 1% SDS),
mixed and the mixture was incubated at room temperature for 5 min. 10 ml of ice cold P3
buffer (3.0 M potassium acetate, pH 5.5) was added, mixed and incubated on ice for 20
min. The samples were centrifuged at 30,000 x g for 30 min at 4°C. The Qiagen-500 tip
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was equilibrated with QBT buffer (750 mM NaCl, 50 mM MOPS, pH 7.0, 15% ethanol
and 0.15% Triton X-100). The supernatant was loaded onto the Qiagen-tip and the tip
was washed twice with 30 ml of QC buffer (1.0 M NaCl, 50 mM MOPS, pH 7.0, 15%
ethanol). The plasmid DNA was eluted from the Qiagen column with 15 ml of QF buffer
(1.25 M NaCl, 50 mM Tris-HCl, pH 8.5, and 15% ethanol) and precipitated with 0.7
volume of isopropanol. The plasmid DNA pellet was collected by centrifugation at 15,000
x g at 4°C for 30 min and washed twice with 70% ethanol. The pellet was air dried for 5
min and redissolved in distilled water. The yield was about 1 (ig/ml bacterial cultures and
the DNA was stored at 4°C for immediate use or stored at -85°C as aliquots for later use.

9.

Preparation, Labeling and Purification of Probes
(1) cDNA probe isolation
The human IGFBP-3 cDNA probe (Wood et al, 1988) was a 475 bp gel-purified

HincHWEcoRI fragment. The human IGFBP-4 cDNA probe was a 470 bp gel-purified
Rsa\ fragment containing exon 1 (LaTour et al., 1990). The human IGFBP-5 cDNA
probe was a 380 bp PCR product corresponding to exon 1 and was prepared in our
laboratory. The human IGFBP-6 cDNA probe (Shimasaki et al., 1991) was a 267 bp
gel-purified Pstl fragment containing midmolecule coding sequence. The human Vitamin
D receptor (VDR) cDNA probe was a 2.1 kb gel-purified EcoRA fragment (Baker et al.,
1988). The human IGF-I receptor cDNA probe was a 750 bp gel-purified EcoRA
fragment (Ullrich et al., 1986). The human IGF-II cDNA probe was a 1 kb EcoK\
fragment (Bell et al., 1985). The human type I procollagen cDNA probe was a 1.8 kb
gel-purified Pst\ fragment (Myers et al., 1981). The human osteocalcin cDNA probe was
a 1.1 kb gel-purified Sad fragment (Celeste et al., 1986). The GAPDH cDNA probe was
a 780 bp gel-purified PstVXbal fragment containing 5'-noncoding and coding regions
(Fort et al., 1985).
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IGFBP-3, -4, -5, -6, type I procollagen, osteocalcin, IGF-I receptor, IGF-II receptor,
VDR, GAPDH cDNA inserts were prepared by restriction enzyme digestion and
electrophoretic separation of the described cDNA insert from vector sequence on a low
melting point agarose gel. Briefly, the plasmid DNA was digested with appropriate
enzyme(s) for 12 to 24 h. The cDNA insert was separated from the vector on a
SeaPlaque low melting point 1% agarose gel using 1 x TBE as the running buffer. After
visualization with ethidium bromide, the desired cDNA insert fragment was cut out of the
gel, melted at 70°C and combined with an equal volume of DEPC water. The cDNA
probe was ahquoted prior to storage at -20°C. The agarose with cDNA probe was melted
at 70°C for 5 min prior to labeling.
(2) cDNA probe labeling and purification
cDNA probes were labeled by the random priming method (Feinburg et al., 1983).
cDNA (50-100 ng) in agarose was diluted in water to 31 pi and boiled for 5 min to
denature the cDNA then cooled on ice for 2 seconds. 10 pi of cDNA labeling mix, 2 pi of
DNase-free BSA (10 mg/ml), 5 pi of a-[32P]-dCTP (66.7 pCi) and 2 pi of the Klenow
fragment of DNA Polymerase 1(1 unit/pl) were added to the denatured cDNA solution in
order. The tube contents were gently mixed and incubated at 37°C overnight.
The labeled probe was separated from unincorporated a-[32P]-dCTP by NACS
chromatography as described in the NACS instruction manual. For cDNA probes longer
than 1 kb, 950 pi of TE buffer with 0.5 M NaCl was added to terminate the random
priming reaction. The NACS column was hydrated with 3 ml TE/2 M NaCl and
subsequently equilibrated with 5 ml of TE/0.5 M NaCl. The cDNA probe mixture was
loaded onto the column twice and the bound cDNA probe was washed with 5 ml of
TE/0.5 M NaCl. The labeled probe was eluted from the column with 400 pi of TE/2 M
NaCl. For cDNA probes less than 1 kb in length, TE/0.2 M NaCl was used instead of the
TE/0.5 M NaCl for the termination, equilibration and washing steps. The labeling
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efficiency was measured by liquid scintillation counting. The specific activity of the probe
was 108 to 109 cpm/pg.
(3) Oligo probe labeling and purification
The oligo probes were end-labeled with T4 kinase by the transfer of
y_[32p]_phosphate to the 5'-hydroxy group of the oligo probe as described (Ausubel et al.,
1994). The 10 pi labeling reaction contained 50-100 ng of oligo, 1 pi 10 x TMDSE, 200
pCi y-[32P]-ATP and 1 unit of T4 Polynucleotide Kinase. The reaction was incubated at
37°C for 45 min and the labeled oligo was purified with a MERmaid™ kit. For 10 pi of
labeling reaction, 30 pi of High Salt Binding Solution and 5 pi of Glassfog was added,
vortexed vigorously and incubated at room temperature for 15 min. The supernatant was
removed by pulse centrifugation and the pellet was washed twice with 300 pi of Ethanol
Wash Solution. The pellet was air-dried for 5 min and the labeled oligo probe was eluted
twice from Glassfog with 50 pi of 65°C DEPC water. The labeling efficiency was
determined by liquid scintillation counting. The specific activity of the probes was 107 to
108 cpm/pg.

10.

RNA Extraction
Total RNA was extracted from cells using a single step acid guanidinium-thiocyanate

phenol-chloroform method as described (Chomczynski et al., 1987). The culture medium
was removed from each 100 mm2 dish of cultured osteoblast or fibroblast cells and 1 ml of
GIT solution was distributed over each dish to lyse the cells. The cell extract was
collected and stored at -80°C or used to isolate total RNA immediately. For RNA
extraction, 0.1 volume of 2 M sodium acetate (pH 4.0), 1 volume of DEPC
water-saturated phenol and 0.2 volume of DEPC water saturated-chloroform/IAA (49:1)
were added to the cell extracts sequentially with complete mixing. The extraction mix was
vortexed vigorously and incubated on ice for 15 min and then centrifuged at 10,000 x g
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for 20 min at 4°C. The upper aqueous layer containing the total RNA was transferred to a
new tube and RNA was precipitated by adding 1 volume of isopropanol and storing at
-20°C overnight. The RNA was collected by centrifugation at 10,000 x g for 20 min at
4°C. The RNA pellet was redissolved in 500 pi of GIT solution and reprecipitated by
adding an equal volume of isopropanol and storing the solution at -20°C overnight. The
RNA was pelleted for 10 min at 14,000 x g at 4°C and washed twice with -20°C 80%
ethanol. The RNA pellet was dried by heating at 65°C for 5 min and dissolved in DEPC
water. The concentration and quality of the RNA was determined by reading the OD at
260 nm and 280 nm, respectively. The isolated RNA was used for northern blot analysis
only if the OD260/OD280 ratio was greater than 1.5. Usually, 50 to 100 fig of RNA was
obtained from five 100 mm2 culture dishes which were 70-80% confluent with
osteosarcoma cells or from ten to twenty culture dishes of normal osteoblast or fibroblast
cells. The RNA was stored at -85°C.

11.

Northern Blot Analysis
(1) Electrophoresis and northern transfer
Electrophoresis and RNA transfer were performed as described (Sambrook et al.,

1989). Briefly, 20 pg of total RNA in 10-20 pi of DEPC water was mixed with 10 pi of
northern sample loading buffer and incubated at 65°C for 5 min to denature the RNA
before loading. The RNA was separated according to size by electrophoresis on an
agarose gel (1.5% agarose in 1 x MOPS with 6.6% formaldehyde) using 1 x MOPS
solution as the running buffer. The RNA in the gel was transferred onto a MagnaGraph
membrane by passive diffusion with 10 x SSC overnight at room temperature. The RNA
was immobilized by UV cross-linking (1.6 KJ/m2) followed by baking at 80°C for 30 min.
The membrane was prewetted with 1 x SSPE, stained with methylene blue solution
(Sambrook et al., 1989) and washed with DEPC-water. The stained 28S (5.1 kb) and 18S
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(1.9 kb) ribosomal RNA bands were used as size markers. The membrane was destained
with 0.2 x SSPE/1% SDS solution immediately before hybridization.
(2) Hybridization and autoradiography
Hybridization for cDNA probes and oligo probes was carried out as described
previously (Sambrook et al., 1989). For cDNA probes, prehybridization was carried out
at 42°C for 2 h in a 5 ml solution containing 6 x SSPE, 5 x Denhardf s, 50% deionized
formamide, 0.1% SDS and 200 pg/ml denatured herring sperm DNA. Hybridization was
carried out in 2.5 ml of the same solution containing 1-10 x 106 cpm/ml of the labeled
cDNA probes at 42°C overnight. The membrane was washed twice with 6 x SSPE/0.1 %
solution at 42°C for 30 min each followed by a final wash with 1 x SSPE/0.1% SDS
solution at 55°C for 30 min.
For oligo probes, membranes were prehybridized in a 5 ml solution containing
6 x SSPE, 5 x Denhardf s and 0.1% SDS at 42°C for 2 h. Membranes were then
hybridized in a solution containing 6 x SSPE, 1 x Denhardt's, 0.1% SDS, 5% dextran
sulfate, 200 pg/ml yeast tRNA and 107 cpm/ml labeled oligo probe at 42°C overnight.
Membranes were washed three times with 6 x SSPE/0.1% SDS at 42°C for 15 min each,
followed by a final wash with 6 x SSPE/0.1% SDS at 55°C for 15 min. After washing,
membranes were autoradiographed with Fuji medicalX-ray film (Fuji Film Co.,
Kanagawa, Japan) at -70°C for 1 to 10 days. The density of a specific mRNA band was
measured with a laser scanning densitometer (Biomedical Instrument, Fullerton, CA). The
GAPDH mRNA transcript levels served as a internal controls for determination of total
RNA loading and transfer. The ratio of the transcript band intensity to the corresponding
GAPDH band intensity was computed for each sample lane. The ratio was assigned a
value of 1 for control and the ratios for all other samples were reported as the percentage
of control.
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12. RT-PCR
(1) cDNA synthesis
The reverse transcription (RT) was carried out using Superscript™ Reverse
Transcriptase according to the manufacturer's instructions. Total RNA in TE buffer was
treated with 0.1 |ig/(il RNase-free DNase I at 37°C for 30 min and then subjected to the
same volume of 0.1 M Tris-HCl (pH 8.3) saturated-phenol/chloroform/IAA (24:24:1) for
protein extraction. Two volumes of -20°C absolute ethanol and 1/10 volume of 2 M
sodium acetate (pH 5.2) were added to the aqueous phase and the RNA was precipitated
at -20°C overnight. 125 to 4,000 ng of DNase I-treated RNA was then reverse
transcribed at 42°C for 10 min in a 20 pi reaction mix containing 100 pmol of the
IGFBP-6 and (3-actin antisense oligo primers, 250 pM of each dNTP (dATP, dTTP,
dCTP, dGTP), 20 units RNasin, 1 x first strand RT buffer and 200 units Superscript
Reverse Transcriptase (RT). The RT reaction was terminated by heating to 70°C for 10
min. The RT was extracted with 20 pi of 0.1 M Tris-HCl (pH 8.0) saturated
phenol/chloroform/IAA (24:24:1). The aqueous phase was transferred to a new tube and
the cDNAs were precipitated with 2 volumes of ethanol and 0.1 volume of sodium acetate
(pH 5.2) at -20°C overnight. The cDNA pellets were collected by centrifugation and
resuspended in DEPC water.
(2) Polymerase chain reaction (PCR)
The PCR reaction (Innis et al., 1990) was performed in a 50 pi reaction volume
containing 1 x NEB Vent buffer, synthesized cDNA, 50 pmole each of the IGFBP-6 sense
and antisense primers, 50 pmole each of the (3-actin sense and antisense primers, 250 pM
each of the dNTPs and 2 units of Vent (exo ) DNA Polymerase. The reaction mixture was
overlaid with 50 pi of fight mineral oil (Promega, Madison, WI). The PCR reaction was
performed in an Eppendorf Micro cycler (Eppendorf Incop oration, Fremont, CA) for 10 to
30 cycles using a denaturing temperature of 98°C (1 min), an annealing temperature of
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60°C (1 min) and extention temperature of 74°C (30 second). Subsequently, 50 pi of
TE-saturated chloroform/IAA (24:1) was used to extract the oil. The aqueous phase was
stored at 4°C for further analysis.

Southern Blot Analysis

13.

Southern blot analysis was performed as described (Sambrook et al., 1989) to
visualize and quantitate the PCR products. 10 to 20 pi of the PCR product solution was
mixed with 1 to 2 pi of the TAE loading buffer and electrophoresized on a 2% agarose gel
(2% NDO agarose in 1 x TAE buffer) using 1 x TAE as the running buffer. After
electrophoresis, the gel was immersed in 0.25 N HC1 with shaking for 10 min and DNA
was denatured by soaking in 1.0 M NaCl/0.5 N NaOH twice for 20 min each at room
temperature. The gel was then neutralized by soaking in 0.5 M Tris-HCl, pH 7.5, 1.5 M
NaCl twice for 20 min each. The separated DNA bands were transferred to
Nytran-BA-83 membranes using 10 x SSC as the transfer buffer as described (Ausubel et
al., 1994). The DNA was immobilized to the membrane by UV crosslinking (1.6 KJ/m2).
Prehybridization was carried out in a solution containing 5 x Denhardt's, 0.5% SDS and
10 mM EDTA at 42°C for 2 h. Hybridization was performed in a solution containing 5 x
SSPE, 5 x Denhartd's, 0.1% SDS, 250 pg/ml yeast tRNA and labeled IGFBP-6 or P-actin
oligo probe (5 x 106 cpm/ml) at 42°C overnight. The membrane was washed twice with
6 x SSC/0.1% SDS at 42°C for 15 min each, followed by a final wash at 55°C for 15 min.
The membrane was autoradiographed with Fuji X-ray film and the bands were quantitated
using an AMBIS scanner (AMBIS Inc., San Diego, CA). The cpm in the IGFBP-6 bands
were normalized to the corresponding cpmin the p-actin bands. The ratio was assigned a
value of 1 for control and the ratios for all other samples were reported as percentage of
control.

CHAPTER THREE
HI. RESULTS
A. Effects of RA on Cell Proliferation and Differentiation
To understand the effect of RA on human bone cell metabolism, we examined the
effects of RA on proliferation and differentiation of cultured normal human osteoblast cells
and human osteoblast-like SaOS-2 osteosarcoma cells.

1.

Effect of RA on Cell Proliferation
To investigate the effect of RA on normal HBC proliferation, cells derived from

human skull fragments were treated with vehicle, RA (lO^M), CS (5%) or RA and CS for
48 h and the cell number was counted. As shown in Fig. 4, RA decreased cell numbers in
basal condition to 87% of control and significantly decreased cell numbers in serum
treated cultures from 230% to 150% of control. The effect of lO*6 M RA on cell
proliferation was also studied in human osteosarcoma, SaOS-2 cells. Because no
difference between RA-treated and vehicle-treated cell numbers was detected after 96
hours, cells were treated with RA (lO-6 M) for 10 days and cell numbers were determined.
The results are illustrated in Fig. 5. After 192 hours and 240 hours of RA treatment, RA
had small effect on SaOS-2 cell proliferation. It decreased cell numbers in basal
conditions to 92% and 88% of vehicle-treated control, respectively. Thus, RA decreased
basal and serum-stimulated cell proliferation in normal HBCs.

2.

Effect of RA on Osteoblast Differentiation
To determine the effect of RA on osteoblast differentiation, the expression of several

biochemical markers of osteoblasts regulated by RA and l,25(OH)2D3 was studied in
SaOS-2 human osteosarcoma cells.
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Figure 4. Effect of RA on proliferation in normal HBCs. HBCs were seeded onto 60
mm diameter plates at a density of 20,000 cells/plate and were maintained in DMEM/10%
CS for 16 to 24 h. Cultures were then changed to serum-free DMEM containing 0.1%
BSA. After 24 h of adaptation, cells were treated with RA (10-6 M), calf serum (CS)
(5%), RA and CS or vehicle (DMSO in the same concentration as RA-treated group) for
48 h. Cells were suspended with 0.05% Trypsin/0.02% EDTA solution and the cell
number in each plate was counted with a hemocytometer. Values are the mean ± SE of
four replicates in the same experiment. A representative of two independent experiments is
shown. Significant difference between control and RA-treated cultures are indicated (*,
P<0.05).
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Figure 5. Effect of RA on proliferation in SaOS-2 cells. SaOS-2 cells were seeded into
6-well plates at a density of 5,000 cells/well in 1 ml DMEM with 10% CS and incubated
for 16 to 24 h. Cultures were changed to serum-free DMEM containing 0.1% BSA. After
24 h of adaptation, cells were treated with RA (10-6 M) or vehicle. The cells were
dissociated with trypsin after the appropriate time peroid and the cell numbers in each well
were counted. Each data point is the mean ± SE of six replicates in the same experiment.
A representative of two independent experiments is shown.
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(1) Dose-dependent effect of l,25(OH)2D3 and RA on mRNA levels of type I
procollagen, ALP and osteocalcin
Human osteosarcoma, SaOS-2 cells were treated with various concentrations of
l,25(OH)2D3 (1010 to lO'8 M) and RA (10'8 to 10-6 M) for 24 h and northern analysis was
carried out as described in Materials and Methods. As shown in Fig. 6, type I
procollagen, ALP and osteocalcin mRNA levels were dose-dependency increased by
l,25(OH)2D3. The maximal observed increases in type I procollagen, ALP and
osteocalcin were 140%, 500% and 860% of control at 10 8 M l,25(OH)2D3, respectively.
The type I procollagen mRNA level was dose-dependently decreased to 30% of control by
lO-6 M RA. ALP and osteocalcin mRNA levels were very low in the presence or absence
of RA in SaOS-2 cells. Similiar results were obtained with untransformed HBCs (data not
shown).
(2) Combination effect of l,25(OH)2D3 and RA on mRNA levels of type I
procollagen, ALP and osteocalcin
Because the baseline levels of ALP and osteocalcin mRNA in SaOS-2 cells are very
low in northern analysis and because l,25(OH)2D3 increases the expression of ALP and
osteocalcin, we studied the effect of RA on 1,2 5 (OH)2D3-stimulated expression of these
genes. Cells were treated with RA (lO 8 M, IQ-6 M), l,25(OH)2D3 (lO 8 M), RA and
l,25(OH)2D3 or vehicle control for 24 h and northern analysis was carried out. As shown
in Fig. 7, type I procollagen mRNA levels were increased by l,25(OH)2D3to 130% of
control and decreased by RA to 25% of control. The addition of RA greatly decreased
l,25(OH)2D3-stimulated procollagen mRNA expression, which was maximally reduced to
18% of vehicle-treated control by 10-6 M RA. Fig. 8 shows the combined effect of
l,25(OH)2D3 and RA on ALP mRNA expression by northern analysis. ALP mRNA levels
were increased by l,25(OH)2D3to 465% of control and this increase was completely
abohshed by the addition of RA (Iff8 M and 10’6 M). Likewise, osteocalcin mRNA

On
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Figure 6. Dose-dependent effect of l,25(OH)2D3 and RA on the mRNA levels of type I procollagen, ALP and osteocalcin in
SaOS-2 cells. Cells were plated at a density of 7,500 cells/cm2 in DMEM/10% CS for 24 h. After 24 h of adaptation in serum-free
DMEM supplemented with 0.1% BSA, cells were treated with various concentrations of l,25(OH)2D3 (lO10 to 10'8 M) or RA (10 8
to lO-6 M) for 24 h. Total RNA was extracted and 20 pg of total RNA was subjected to northern analysis to determine the type I
procollagen, ALP, osteocalcin and GAPDH mRNA expression pattern as described in Materials and Methods. GAPDH mRNA
levels were used to normalize for RNA loading and transfer. Results are representative of two independent experiments.
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Figure 7. Combination effect of RA and l,25(OH)2D3on the expression of type I
procollagen mRNA in SaOS-2 cells. Cells were treated with RA (lO 8 M, 10-6 M),
1,25(OH)2D3(10-8 M), RA and l,25(OH)2D3 or vehicle (DMSO and absolute ethanol at
the same concentrations as RA and l,25(OH)2D3-treated group) for 24 h. Northern
analysis of type I procollagen mRNA levels was carried out as described in Materials and
Methods. +, 108 M; ++, 10"6 M. Results are representative of two individual experiments.
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Figure 8. Combination effect of RA and l,25(OH)2D3 on the expression of ALP mRNA in SaOS-2 cells. Cells were treated as
described in Fig. 4. Northern analysis to quantitate ALP mRNA levels was carried out as described in Materials and Methods. +,
10'8 M; ++, 10-6 M. Similiar results were obtained in another independent experiment.
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expression was also increased by l,25(OH)2D3to 920% of control and this increase was
inhibited to 290% of control by the addition of RA. These results are illustrated in Fig. 9.
Therefore, RA consistently inhibited l,25(OH)2D3-stimulated expression of type I
procollagen, ALP and osteocalcin gene in SaOS-2 cells (Table 2).
(3) RA regulation of ALP activity
We have previously shown that RA decreased l,25(OH)2D3-stimulated ALP mRNA
levels in SaOS-2 cells. To determine if this change was accompanied by a corresponding
change in ALP activity, cells were treated with various concentrations of RA (1012 to IQ-6
M) in the presence or absence of l,25(OH)2D3 (10 8 M) for 48 h. ALP activity was
measured as described in Materials and Methods. As shown in Fig. 10, RA significantly
decreased the baseline level of ALP activity in a dose-dependent manner. The maximal
response occurred at 10-6 M RA at which point ALP activity was decreased to 45% of
vehicle-treated control. l,25(OH)2D3 stimulated ALP activity to 280% of control and this
stimulation was dose-dependency inhibited by RA, maximally to 90% of vehicle treated
control. These results are quahtatively consistent with the ALP mRNA level changes
(Table 2).

3.

VDR Expression Regulated by l,25(OH)2D3 and RA
It is known that the action of l,25(OH)2D3 on expression of the osteoblast

differentiation phenotype is mediated by its receptor, VDR (Norman, 1980). To
determine if the effect of RA on osteoblastic cell differentiation was mediated by altering
VDR mRNA expression, SaOS-2 cells were treated with different doses of l,25(OH)2D3
(lO-9 to lO-7 M) and RA (108 to 10-6 M) for 24 h. Northern analysis of the VDR mRNA
is shown in Fig. 11. l,25(OH)2D3 increased VDR mRNA levels in a dose-dependent
manner, maximally to 200% of control at 10'7 M l,25(OH)2D3. In contrast, 10"6 M RA
decreased VDR expression to 80% of vehicle-treated control. With combinations of RA
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Figure 9. Combination effect of RA and l,25(OH)2D3 on the expression of osteocalcin
mRNA in SaOS-2 cells. Cells were treated with RA (10-6 M), l,25(OH)2D3 (lO 8 M), RA
and l,25(OH)2D3 or vehicle for 24 h. RNA was extracted and subjected to northern
analysis to determine osteocalcin mRNA levels. The data presented are representative of
three individual experiments.
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Table 2. Effect of RA and l,25(OH)2D3on osteoblastic differentiation phenotypes in
SaOS-2 cells. The data presented in this table are reported as percentage of corresponding
controls. Each group of data are mean from two independent experiments. The
representative results are presented in Fig. 4 through Fig. 7.

Control

RA

VitD

RA+VitD

Procollagen mRNA

100

25

131

18

Osteocalcin mRNA

100

98

920

290

ALP mRNA

100

80

465

81

ALP activity

100

45

280

90

Os

Figure 10. Regulation of ALP activity by RA and l,25(OH)2D3in SaOS-2 cells. Cells were plated onto a 24-well plate at 20,000
cells/well and treated with RA (1012 to 10-6 M), l,25(OH)2D3 (10 8 M), RA and l,25(OH)2D3 or vehicle for 48 h. ALP activity was
measured as described in Materials and Methods and the results are reported as % of corresponding controls. Values are the
mean±SE of six replicates from four individual experiments. Clear bars represent treatment with RA alone, black bars represent RA
and l,25(OH)2D3-treated groups. Significant differences (*, P < 0.05) were determined by ANOVA program, a, significantly
different from vehicle-treated control; b, significantly different from vehicle-treated control; c, significantly different from
l,25(OH)2D3-treated groups.
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Figure 11. Dose-dependent effect of l,25(OH)2D3 and RA on VDR mRNA expression in SaOS-2 cells. Cells were treated with
varying concentrations of l,25(OH)2D3 (10 9 to lO-7 M) or RA (lO 8 to 10-6 M) for 24 h. Total RNA was extracted and subjected to
northern analysis as described in Materials and Methods. VDR mRNA levels (5.0 kb transcript) were normalized to the level of
GAPDH mRNA (1.3 kb transcript). An independent experiment was performed which yielded similar results.
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(10-6 M) and l,25(OH)2D3 (lO8 M), VDR mRNA expression was decreased to 70% of the
levels found in cells treated with l,25(OH)2D3 alone (Fig. 12). Changes in VDR mRNA
expression correlated somewhat with changes in osteoblastic differentiation phenotype
marker expression.

B. Effect of RA on the IGF System
Several lines of evidence indicate that the RA induced reduction in cell proliferation
and differentiation could be mediated by the IGF system: 1) IGF-I and -II stimulate
osteoblast cell proliferation and IGF-II stimulates differentiation of HBCs (Rosen et al.,
1994); 2) human osteoblast cells produce IGF-II, type I and II receptors and stimulatory
and inhibitory IGFBP-3, -4, -5 and -6 (Mohan, 1991); 3) l,25(OH)2D3, a hormone similar
to RA, recruits IGFBP-4 to mediate inhibition of cell proliferation (Scharla et al., 1993);
4) the mitogenic effects of both IGF-I and IGF-II are mediated by IGF-I receptor
(Conover et al., 1986; Furlanetto et al., 1987). Therefore, we proposed the hypothesis
that RA affects osteoblast cells by altering the synthesis of one or more IGF system
components. To determine if IGF system components were regulated, we investigated the
effect of RA on the expression of IGF-II, IGF receptor and IGFBP-3, -4, -5 and -6 in
untransformed and transformed human osteoblast-like cells.

1.

IGF-II Expression
We first studied the effect of RA on IGF-II mRNA expression. Because IGF-II

increases HBC proliferation, we thought that RA could simply decrease proliferation rates
by reducing the amount of IGF-II synthesized. To test this, HBCs were treated with
various concentrations of RA ranging from 1012 M to IQ-6 M for 24 h and IGF-II
transcript levels were quantitated by northern analysis. As shown in Fig. 13, the IGF-II
mRNA levels were not significantly increased by RA in normal HBCs. However, the

00

Figure 12. Combination effect of RA and l,25(OH)2D3 on the expression of VDR mRNA in SaOS-2 cells. Cells were treated
with RA (10-6 M), l,25(OH)2D3 (10-8 M), RA and l,25(OH)2D3 or vehicle for 24 h. Northern analysis was carried out as described
in Materials and Methods. Results are representative of two independent experiments.
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Figure 13. Dose-dependent effect of RA on IGF-11 mRNA expression in normal
HBCs. Cells were treated with various concentrations of RA ranging from 10-12 M to lO-6
M for 24 h. Total RNA was extracted and subjected to northern analysis with an IGF-II or
GAPDH cDNA probe.
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mRNA levels of IGF-II in SaOS-2 cells were increased by RA dose-dependency as shown
in Fig. 14. The abundance of the 6.0 kb and 5.3 kb IGF-II transcripts were increased by
RA to 250% and 180% of control, respectively. The level of the translated 4.9 kb
IGF-II transcript (Nielson et al., 1990) was increased to 130% of control by RA.
Surprisingly, RA increased the IGF-II transcripts differentially. To investigate the time
course of the effect of RA on the steady state IGF-II mRNA levels, SaOS-2 cells were
treated with RA (lO-6 M) or vehicle for 1 to 24 h, mRNA levels were determined by
northern analysis as shown in Fig. 15. A 500% increase in 6.0 kb, 300% increase in the
5.3 kb and 150% increase in the 4.9 kb IGF-II transcript levels were observed at 24 h,
indicating that the action of RA on IGF-II expression was delayed. The results of this
study indicated that effects on IGF-II by RA could not account for a reduction in cell
proliferation or differentiation.

2.

IGF-I and IGF-II Binding to Osteoblast Cells
A decrease in IGF binding resulted from IGF receptor change could also account for

a decrease in cell proliferation. The effect of RA on labeled IGF-I and IGF-II binding to
the osteoblast cell surface was conducted. Normal HBCs were treated with RA (10-6 M)
or vehicle for 48 h and the binding assay with labeled IGF-I and IGF-II was performed as
described in Materials and Methods. As shown in Table 3, RA decreased IGF-I and -II
binding sites on cell surface to 36% and 52% of control, respectively. This could account
for the reduction of human bone cell proliferation and differentiation by RA.

3.

IGF-I Receptor mRNA Expression
We found that RA decreased IGF-I and -II binding to the HBC surface. To study if

this resulted from a decrease in IGF-I receptor expression, the steady state mRNA levels
of IGF-I receptor in RA, l,25(OH)2D3, RA and l,25(OH)2D3 or vehicle-treated normal
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Figure 14. Dose-dependent effect of RA on IGF-II mRNA expression in SaOS-2 cells.
Cells were treated as described in Fig. 10 and northern analysis of IGF-II mRNA levels
was carried out as described in Materials and Methods. Results are representative of two
individual experiments.
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Figure 15. Time course effect of RA on IGF-II mRNA expression in SaOS-2 cells.
Cells were treated with RA (10-6 M) or vehicle for the indicated time intervals from 1 to
24 h. Northern analysis of IGF-II mRNA levels was carried out. An independent
experiment was performed which yielded similar results.
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Table 3. Effect of RA on IGF-I and IGF-II binding to normal HBCs. Cells were
treated with RA (lO-6 M) or vehicle for 48 h. IGF-I and IGF-II binding assays were
carried out as described in Matena/s and Methods. Within the linear range of the
relationship between cpm of [125I]-labeled IGF-I or IGF-II bound to the cells and
increasing concentrations of corresponding cold IGF-I or IGF-II added, the binding of
[125I]-labeled IGF-I or IGF-II to the cell surface was calculated and converted to the
number of binding sites/cell. The values for binding sites/cell in vehicle-treated cells were
assigned a value of 1 for control and the binding sites/cell in RA-treated cells were
compared to this control. Results are expressed as % of corresponding control. Data
presented are mean ± SE of six replicates in the same experiment. A representative of two
independent experiments is shown.

Control

RA

IGF-I binding

100±6

36±4 **

IGF-n binding

100±9

52±3 **

**: P < 0.01
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HBCs were measured by northern analysis. As shown in Fig. 16, IGF-I receptor mRNA
levels were decreased by RA and l,25(OH)2D3to 30% and 35% of vehicle-treated
control, respectively. This result is consistent with our findings that IGF-I and -II binding
was decreased by RA. It suggests that RA effects on HBCs could be modulated in part by
a reduction in IGF receptors.

4.

IGFBP Expression
(1) Effect of RA on IGFBP mRNA levels in human osteoblast and fibroblast

cells
Normal HBCs, human osteosarcoma SaOS-2 and U2-OS cells as well as human skin
fibroblasts were treated for 24 h with either vehicle or various concentrations of RA
ranging from 1012 to IQ-6 M. Multiple cell strains were utilized to determine if expression
patterns of the various IGFBPs were consistently altered in cells of mesenchyml origin and
in cells representing both a transformed and untransformed phenotype. After treatment,
total RNA was isolated and subjected to northern analysis to determine the relative
IGFBP-3, -4, -5 and -6 mRNA expression patterns in response to RA. Fig. 17 illustrates
the results of representative northern analysis from two to five independent experiments in
which only the bands of interest are shown. Fig. 18 is a composite of the IGFBP mRNA
data from all the experiments.
As shown in Fig. 17 and 18A, RA significantly stimulated accumulation of IGFBP-3
mRNA (2.6 kb) levels to 580% of control in SaOS-2 cells (Fig. 17B) and increased
IGFBP-3 mRNA levels in HBCs and HSF cells to a less extent (< 150% of control) (Fig.
17A, 17D). IGFBP-3 mRNAs were not detectable in U2-OS cells in any conditions (Fig.
17C). The maximal observed stimulation of IGFBP-3 occurred at 10’8 M RA in SaOS-2
cells, at which point the IGFBP-3 mRNA level was increased to 680% of control.
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Figure 16. Effect of RA and l,25(OH)2D3 on IGF-I receptor mRNA expression in
normal HBCs. Cells were treated with lO-6 M RA, 10 8 M l,25(OH)2D3, RA and
l,25(OH)2D3 or vehicle for 24 h. Total RNA was extracted and subjected to northern
analysis. IGF-I receptor mRNA (9.0 and 11 kb transcripts) levels were quantitated as
described in Materials and Methods.
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Figure 17. Dose-dependent effect of RA on the steady state levels of IGFBP mRNA in
various cell types. Cells were plated at a density of 7,500 cells/cm2 for 24 h. After 24 h
of adaptation to serum-free DMEM supplemented with 0.1% BSA, cells were treated with
1012 to 10-6 M RA for 24 h. RNA was extracted and 20 pg of total RNA was subjected to
northern blot analysis as described in Materials and Methods to determine the mRNA
levels for IGFBP-3, -4, -5 and -6 in response to RA. GAPDH mRNA levels were used to
normalize RNA loading and transfer. Northern blot analysis of RNA from normal HBCs
(A), SaOS-2 cells (B), U2-OS cells (C) and human skin fibroblasts (HSF) (D). Data
presented are representative of two to five individual experiments.
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Figure 18. Summary of IGFBP mRNA level changes in response to various RA doses.
The density of the specific IGFBP or GAPDH band was measured with a laser
densitometer. The GAPDH transcript served as an internal control for the each sample for
RNA loading and transfer. The ratio of IGFBP transcript band intensity to the
corresponding GAPDH band intensity was computed for each sample lane. The ratio was
assigned a value of 1 for control and the ratios for all other samples were reported as
percentage of this control. IGFBP-3 (A), IGFBP-4 (B), IGFBP-5 (C) and IGFBP-6 (D).
The values are the mean ± SD from three to five independent experiments. Only the values
of IGFBP-3, -4, -5 and -6 from HBCs are mean from two independent experiments.
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IGFBP-3 mRNA levels dropped to 143% of control at the higher 10"6 M RA dose. These
data suggest that the effect of RA on IGFBP-3 expression was variable and cell
transformation state dependent. IGFBP-4 mRNA (2.4 kh) levels were increased by RA in
a dose-dependent manner (Fig. 17 and Fig. 18B). They were stimulated maximally by lO-6
M RA to 225%, 390%, 310% and 180% of control in HBCs (Fig. 17A), SaOS-2 cells
(Fig. 17B), U2-OS cells (Fig. 17C) and HSF cells (Fig. 17D), respectively. The effect of
RA on IGFBP-4 mRNA expression was consistently stimulatory and was not cell line
dependent.
As shown in Fig. 17 and Fig. 18C, IGFBP-5 mRNA (6.0 kb) levels were dose
dependency decreased by RA. Detectable levels of IGFBP-5 mRNA were not expressed
in SaOS-2 cells under non-stimulated conditions. In untransfromed HBCs (Fig. 17A) and
HSF cells (Fig. 18D), IGFBP-5 mRNA levels were dramatically decreased by 10-6 M RA
to 35% and 43% of control, respectively. Although the changes in IGFBP-5 mRNA levels
in response to RA in osteosarcoma U2-OS cells was not as pronounced as observed in
untransformed human osteoblast and fibroblast cells, IGFBP-5 mRNA levels were
decreased maximally to 76% of control (Fig. 17C). The effect of RA on IGFBP-5 mRNA
expression was consistently inhibitory.
The IGFBP-6 mRNA (1.3 kb) level was dramatically increased by RA in a dose
dependent manner as shown in Fig. 17 and Fig. 18D. Doses of RA as low as 1010 M
stimulated an increase in IGFBP-6 (400% of control), but lO 8 M and 10-6 M RA
dramatically increased IGFBP-6 mRNA levels at 24 h. In HBCs, IGFBP-6 mRNA levels
were increased to 510% and 1,000% of control by lO 8 M and 10-6 M RA, respectively
(Fig. 17A). In SaOS-2 cells, IGFBP-6 mRNA levels were increased to 1,200% and
1,900% of control by lO 8 M and 10-6 M RA, respectively (Fig. 17B). In U2-OS cells,
IGFBP-6 mRNA levels were increased to 750% and 1,100% of control by lO 8 and 10-6 M
RA, respectively (Fig. 17C). In human fibroblast cells, IGFBP-6 mRNA levels were
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increased to 850% and 1,300% of control by 10'8 M and 10-6 M RA, respectively (Fig.
17D). The most dramatic effect of RA on IGF system components thus far occurred with
IGFBP-6. RA consistently stimulated a 10 to 20 fold increase in IGFBP-6 mRNA levels.
The concentration of RA required to half maximally stimulate IGFBP-3, -4, -5 and -6
expression changes varied from 10'9 M to 10 7 M. IGFBP-3 and -5 responded to lower
doses of RA than did IGFBP-4 and -6. Because both sensitivity and magnitude of the
responses to RA are different for the various IGFBPs, we proposed that the RA effects on
different IGFBPs may be mediated by distinct mechanisms.
(2) Comparison of the effects of RA and l,25(OH)2D3 on IGFBP expression
In a previous study with human osteosarcoma and untransformed HBCs,
1,25(OH)2D3 increased differentiation and inhibited proliferation with a corresponding
increase in IGFBP-3 and -4 (Scharla et al., 1993). Because RA and l,25(OH)2D3 both
increased IGFBP-3, -4 expression, yet had differential effects on osteoblast differentiation,
we proposed the hypothesis that RA and l,25(OH)2D3 might differentially regulate the
expression of other IGFBPs in human osteoblasts. To compare the effects of RA and
l,25(OH)2D3 on IGFBP expression, SaOS-2 cells were treated with various
concentrations of l,25(OH)2D3 (lO 9 to 10*7 M) and RA (lO 8 to K)-6 M) for 24 h and
IGFBP mRNA levels were determined by northern analysis (Fig. 19). The IGFBP-3
mRNA levels were progressively increased maximally to 250% of control with 10 7 M
l,25(OH)2D3 and 580% of control with 10-6 M RA. The levels of IGFBP-4 mRNA were
progressively increased by both l,25(OH)2D3 and RA, maximally to 320% and 450% of
control, respectively. Although RA and l,25(OH)2D3 similarly affected IGFBP-3 and -4
mRNA levels, RA markedly increased IGFBP-6 mRNA levels to 1,100% of control, but
l,25(OH)2D3 alone had no effect on IGFBP-6 mRNA expression. IGFBP-5 mRNA levels
were not detected either in l,25(OH)2D3-treated or in RA-treated SaOS-2 cells. However,
IGFBP-5 mRNA levels were decreased to 43% or 19% of control by treatment with

o
o

Figure 19. Dose-dependent effect of l,25(OH)2D3 and RA on IGFBP mRNA expression in SaOS-2 cells. Cells were treated
with various concentrations of l,25(OH)2D3 (lO 9 to lO 7 M) or RA (lO 8 to 10-6 M) for 24 h. mRNA levels of IGFBP-3
, -4 and -6
were determined by northern analysis.
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l,25(OH)2D3 or RA in normal HBCs, respectively (Fig. 20). Because of the differences in
the regulation of IGFBP-6 by RA and l,25(OH)2D3, it is possible that the distinct effects
of RA and l,25(OH)2D3 on osteoblast differentiation result in part from differences in RA
regulated IGFBP-6 expression.
(3) Combination effect of RA and l,25(OH)2D3 on IGFBP expression
Because both RA and l,25(OH)2D3 regulate IGFBP expression and because the
receptors for 9-cis RA and l,25(OH)2D3 can form beterodimers to regulate gene
expression, the combination effect of RA (IQ-6 M) and l,25(OH)2D3 (108 M) on the
expression of IGFBPs was studied in HBCs and SaOS-2 cells by northern analysis to
determine if RA and l,25(OH)2D3 interact. As shown in Fig. 20, neither RA,
l,25(OH)2D3nor combinations of the agents significantly affected either IGFBP-3 or -4
mRNA expression in HBCs. In SaOS-2 cells, both RA and l,25(OH)2D3 increased
IGFBP-3 and -4 expression. However, combination treatments with both reagents did not
significantly affect IGFBP-3 and -4 expression compared with RA or l,25(OH)2D3
treatments alone (Fig. 21). IGFBP-5 mRNA levels were decreased by RA and
l,25(OH)2D3to 19% and 43% of control, respectively, in HBCs. Combination treatment
did not decrease IGFBP-5 mRNA levels more than RA alone (Fig. 20). IGFBP-6 mRNA
expression was not regulated by l,25(OH)2D3, but l,25(OH)2D3 significantly increased
RA-stimulated IGFBP-6 mRNA expression from 448% to 587% of control in SaOS-2
cells (Fig. 21) and from 1,000% to 1,500% of control in HBCs (Fig. 20). These results
suggest that the l,25(OH)2D3 or l,25(OH)2D3-induced secondary responses assist the
stimulatory effect of RA on IGFBP-6 mRNA expression. A summary of the IGFBP
mRNA levels in SaOS-2 cells and HBCs in response to RA and l,25(OH)2D3is shown in
Table 4.
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Figure 20. Combination effect of RA and l,25(OH)2D3on IGFBP mRNA expression
in normal HBCs. Cells were treated with RA (10-6 M), l,25(OH)2D3 (lO 8 M), RA and
l,25(OH)2D3 or vehicle for 24 h. mRNA levels of IGFBP-3, -4, -5 and -6 were determined
by northern analysis.
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Figure 21. Combination effect of RA and l,25(OH)2D3on IGFBP mRNA expression in SaOS-2 cells. Cells were treated with
RA (lO-6 M), l,25(OH)2D3 (10'8 M), RA and l,25(OH)2D3 or vehicle for 24 h. Northern analysis was carried out to determine the
mRNA levels of IGFBP-3, -4 and -6. Data presented is a representative of two individual experiments.
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Table 4. Combination effect of RA and l,25(OH)2D3 on IGFBP mRNA levels in
human osteoblast cells. These values are derived from Fig. 17 and Fig. 18. The density of
the specific IGFBP and GAPDH band was measured with a laser densitometer. The ratio
of IGFBP transcript band intensity to the corresponding GAPDH band intensity was
computed for each sample lane. The ratio was assigned a value of 1 for control and the
ratios for all other samples were reported as percentage of control.

HBCs

SaOS-2 cells

BP-3 BP-4 BP-5 BP-6

BP-3

BP-4

BP-6

Control

100

100

100

100

100

100

100

RA

105

110

19

1000

283

421

448

VitD

103

102

43

106

236

193

111

RA+VitD

98

105

15

1500

322

307

587
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(4) Regulation of IGFBP levels by RA
RA significantly increased the mRNA abundance of IGFBP-3, -4 and -6 and
decreased the IGFBP-5 mRNA levels in human osteoblast cells. To determine if these
changes were reflected in the levels of IGFBPs in the CM, normal HBCs and SaOS-2 cells
were treated lO-6 M RA for 48 h, CM was collected and IGFBP levels were determined by
western ligand blot analysis and IGFBP-5 RIA. Fig. 22A illustrates ligand blot analysis
with [125I]-IGF-II from two independent experiments showing the effect of RA on IGFBP
levels in the CM of normal HBCs. RA increased the 38-42 kDa (IGFBP-3) and 29-32
kDa IGFBPs, but had no effect on the 24 kDa (IGFBP-4) IGFBPs. The amount of
IGFBP-3 in the CM was increased to 130%-150% of control. The 29-32 kDa IGFBP was
increased to 300% of control. Fig. 22B is a ligand blot analysis showing the effect of RA
on IGFBP levels in the CM of SaOS-2 cells. RA significantly increased the 38-42 kDa
IGFBP-3 to 550%-700% of control and increased the 29-32 kDa protein to 300%-400%
of control. Different from the effect on normal HBCs, RA significantly increased the
IGFBP-4 level to 300% of control in SaOS-2 cells. Since IGFBP-5 (29-32 kDa) and
IGFBP-6 (30-34 kDa) have similiar molecular weights, their identity could not be
established by ligand blot analysis alone. Therefore, the amount of IGFBP-5 in the CM of
normal HBCs and SaOS-2 cells was quantitated with a specific RIA. As shown in Table
5, baseline levels of IGFBP-5 (17.5 ng/ml) were decreased to 43% of control (7.5 ng/ml)
by RA in normal HBCs. In SaOS-2 cells, baseline levels of IGFBP-5 (3.9 ng/ml) were
decreased by RA to 45% of control (1.7 ng/ml). Because IGFBP-5 protein levels in the
CM of both normal HBCs and SaOS-2 cells were decreased by RA, it is probable that the
29-32 kDa IGFBP which was increased after RA treatment is IGFBP-6. Therefore,
changes of the IGFBP protein level were correlated with corresponding changes of mRNA
level, suggesting that changes in IGFBP protein level results from the corresponding
IGFBP mRNA changes.
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Figure 22. Western ligand blot analysis of IGFBP levels in the CM of normal HBCs
and SaOS-2 cells Cells were treated with RA (lO-6 M) or vehicle for 48 h. CM was
collected and subjected to western ligand blot analysis with [125I]-IGF-II to determine the
IGFBP level as described in Materials and Methods. (A) Normal HBCs, (B) SaOS-2 cells.
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Table 5. Effect of RA on IGFBP-5 levels in the CM of normal HBCs and SaOS-2
cells. Cells were treated with RA (lO-6 M) or vehicle for 48 h. CM was collected and
subjected to IGFBP-5 RIA analysis as described in Materials and Methods. The values are
mean ± SE of four replicates in the same experiment. A representative of two independent
experiments is shown.

SaOS-2 cells

Normal HBCs

IGFBP-5(ng/ml)

**: P<0.01

Control

RA

Control

RA

17.5±0.2

7.5±0.4 **

3.8±0.2

1.7±0.2 **
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In summary, RA altered expression of several components of the IGF system. RA
increased inhibitory IGFBP-3, -4 and -6 expression and decreased stimulatory IGFBP-5
expression and IGF-I receptor expression. l,25(OH)2D3 also increased IGFBP-3 and -4,
and decreased IGFBP-5 and IGF-I receptor expression but did not affect IGFBP-6.

C. Mechamsm(s) by which RA Regulates IGFBP Expression
1.

Time Course of the Effect of RA on Steady State mRNA Levels of IGFBP
In order to understand the mechanism(s) by which RA regulates IGFBP mRNA

levels, the time course effect of RA on IGFBP-3, -4 and -6 mRNA levels was determined
in SaOS-2 cells. Because SaOS-2 cells do not express IGFBP-5, the time course effect of
RA on IGFBP-5 mRNA levels was studied using human skin fibroblasts. Fig. 23A shows
representative results using SaOS-2 cells. IGFBP-3, -4 and -6 mRNA levels were
progressively increased by RA. Small but detectable increases in IGFBP-3, -4 and -6
mRNA levels by RA were detected within 1-6 h of treatment, however, dramatic changes
in mRNA levels occurred from 24 to 48 h. There was no significant difference in
IGFBP-3 mRNA levels between the RA-treated and vehicle-treated group at 24 and 48
hours, because IGFBP-3 mRNA levels in both control and RA-treated cells were elevated
over 900% of the 0 time control. Perhaps production of IGF-II and other factors by
HBCs could contribute to the increase in control cell populations. IGFBP-4 mRNA was
maximally stimulated by RA to 350% of control at 48 h. IGFBP-6 mRNA increased to
300% of control at 6 h and progressively increased to 1,500% and 2,700% of control at
24 and 48 h, respectively. Fig. 23B illustrates the time course effect of RA on IGFBP-5
mRNA in human fibroblast cells. IGFBP-5 mRNA expression increased with time over 48
h in control cultures. RA reduced this increase in IGFBP-5 expression at both 24 and 48 h
and maximally reduced it to 30% of vehicle-treated control at 48 h.
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Figure 23. Time course effect of RA on IGFBP mRNA levels. Cells were treated with
RA (1 O'6 M) or vehicle for various time intervals from 1 to 48 h. Northern blot analysis
was carried out as described in Materials and Methods. (A) Time course effect ofRA on
IGFBP-3, -4 and -6 mRNA levels in SaOS-2 cells. (B) Time course effect of RA on
IGFBP-5 mRNA levels in human skin fibroblasts. An independent experiment was
performed which yielded a similar result.
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2.

Effect of Cycloheximide on RA-Regulated IGFBP Expression
To determine whether the RA stimulated increases in IGFBP-3, -4 and -6 expression

and the reduction in IGFBP-5 expression were dependent on de novo protein synthesis,
normal HBCs and SaOS-2 cells were treated with 10-6 M RA for 24 h in the presence or
absence of 10 pM cycloheximide (CHX), a dose known to inhibit protein synthesis in
human osteoblasts by 90% (Keyeune-Nyombi et al., 1991), and was subjected to northern
analysis. As shown in Fig. 24A, neither RA, CHX or RA and CHX had a significant effect
on IGFBP-3 and -4 mRNA levels in HBCs. In SaOS-2 cells, CHX resulted in a 150% to
200% increase in IGFBP-3 and -4 mRNA levels, but CHX did not significantly affect the
RA-stimulated increase in IGFBP-3 and -4 mRNA levels (Fig. 24B). In HBCs, CHX
reduced IGFBP-5 mRNA levels at 24 h by greater than 50% of control and contributed to
a further reduction of IGFBP-5 mRNA levels by RA (Fig. 24A). In both SaOS-2 cells and
HBCs, CHX had no effect on IGFBP-6 mRNA levels in controls but greatly inhibited RA
induced increases in IGFBP-6 mRNA levels by 90% (Fig. 24A and 24B). These data
suggest that de novo protein synthesis is required for RA-stimulated IGFBP-6 steady state
mRNA accumulation, but not required for other IGFBPs.

3.

Effect of RA on IGFBP mRNA Stability
To test the hypothesis that RA affects on steady state levels of IGFBP mRNA were in

part due to alterations in IGFBP mRNA stability, IGFBP-3, -4, -5 and -6 mRNA levels
were determined after inhibiting mRNA transcription with 5,6-Dichloro-l-(3-D
ribofuranosyl benzimidazole (DRB). Cells were treated with RA (10-6 M) or vehicle for
24 h and then 20 pg/ml DRB (a dose which reduces basal IGFBP mRNA abundance in
SaOS-2 cells by more than 80%) was added. IGFBP mRNA levels were determined in
samples of total RNA extracted from cells at different time points after DRB addition.
Figure 25 shows northern analysis of mRNA levels for IGFBP-3, -4 and -6 in SaOS-2 cells

Q\

Figure 24. Effect of cycloheximide on RA-regulated IGFBP mRNA levels. Cells were treated with RA (10*6 M) or vehicle in the
presence or absence of cycloheximide (10 pM) for 24 h. Northern analysis was carried out in HBCs (A) and in SaOS-2 cells (B) as
described in Materials and Methods. Results are representative of two independent experiments.
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Figure 25. Effect of RA on the stability of IGFBP mRNAs. Cultures were treated with
vehicle or RA (10-6 M) for 24 h and DRB (20 ng/ml) was added thereafter for various
periods of time. The IGFBP and GAPDH mRNA levels were determined by northern
analysis. The relative levels of IGFBP-3, -4 and -6 mRNA from SaOS-2 cells and IGFBP5 mRNA from HBCs were determined by laser densitometry of autoradiographs. The
IGFBP and GAPDH mRNA levels were normalized to the density of the 28 S rRNA bands
to account for loading and transfer. The half-life of each IGFBP mRNA was estimated
from a plot of the decay curves. IGFBP (—) and GAPDH (—) mRNA levels of control
(O) and RA (0) treated cells are expressed as a percentage of the mRNA level at 24 h
before DRB addition. Each time point represents the mean ± SE (n=4) from two
independent experiments. Northern blot analysis and decay curves of IGFBP-3 (A),
IGFBP-4 (B), IGFBP-5 (C) and IGFBP-6 (D).
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and for IGFBP-5 in untransformed HBCs. The decay curves of IGFBP mRNA in RA and
vehicle-treated cultures are also shown in Fig. 25. The half-life of the IGFBP-3 mRNA in
vehicle- and RA-treated cells was 18 and 23 h, respectively (Fig. 25 A). The half-life of
IGFBP-4 mRNA in vehicle and RA-treated cells was 28 and 35 h, respectively (Fig. 25B).
The IGFBP-5 mRNA half-life in vehicle and RA-treated cells was 23 and 50 h,
respectively (Fig. 25 C), which is opposite of the result expected from inhibiting effect of
RA on steady state IGFBP-5 mRNA levels. The IGFBP-6 mRNA half-life in vehicle and
RA-treated cells was 22 and 31 h, respectively (Fig. 25D). This effect on IGFBP-6 is not
enough account for the large increase in steady state IGFBP-6 mRNA levels induced by
RA. Therefore, RA increased the stability of all four IGFBP mRNAs and increased the
stability of IGFBP-5 mRNA to the largest extent, but effects on IGFBP-5 and -6 mRNA
stability cannot account for the effects of RA on steady state mRNA levels.

4.

Induction of IGFBP-6 hnRNA by RA
IGFBP-6 mRNA levels were dramatically stimulated by RA but the stability of

IGFBP-6 cytoplasmic mRNA was minimally affected. These results suggest that
transcriptional and/or early post-transcriptional mechanism(s) are involved in the RA
stimulated increase in IGFBP-6. Because the hnRNA level is an index of the amount of
nascent chains transcribed, hnRNA levels for a gene are an indirect measure of
transcriptional activity of the gene. We determined the effect of RA on the IGFBP-6
hnRNA levels using a newly developed quantitative RT-PCR approach using primers
which specifically amplify intron sequences. Total RNA derived from SaOS-2 cells served
as the reverse transcription template. The primer pair used in the PCR reaction to amplify
IGFBP-6 hnRNA was BP-6A (sense) and BP-6E (antisense) shown in Fig. 26. The
primers were designed using the Primer 2 program to amplify intron 2 of the human
IGFBP-6 sequence, based on coding sequence published by Shimasaki et al. (1991) and
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Figure 26. Sequence of intron 2 in the human IGFBP-6 gene. Intron 2 from the human
IGFBP-6 gene contained within a PI clone obtained from Genome Systems (St. Louis,
MO) was sequenced (unpublished data) at the Loma Linda University, Center for Gene
Therapy using site specific oligo primers (BP6-A and BP6-B) corresponding to exon 2
and exon 3 sequence that was previously published (Shimasaki et al., 1993). Exon
sequence appears as uppercase letters and intron sequence appears as lowercase letters.
Oligo corresponding to BP6-A and BP6-E constituted the primer pair for RT-PCR
analysis, oligo BP6-G was the probe used for southern hybridization.
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BP6-A

►
1

TGTTGCAGAG GAGAATCCTA GGAGAGTAAA CCCCAAGCAG GCACTGCCCG CCCACAGGAT
ACAACGTCTC CTCTTAGGAT CCTCTCATTT GGGGTTCGTC CGTGACGGGC GGGTGTCCTA

61

GTGAACCGCA GAGACCAACA GAGGAATCCA GGCACCTCTA CCACGCCCTC CCAGCCCAAT
CACTTGGCGT CTCTGGTTGT CTCCTTAGGT CCGTGGAGAT GGTGCGGGAG GGTCGGGTTA
exon2/intron2

121

181

TCTGCGGGTG TCCAAGACAC TGAGATGgtg cgtttggatc tggtagggag caggaggggt
AGACGCCCAC AGGTTCTGTG ACTCTACcac gcaaacctag accatccctc gtcctcccca
BP6-G Probe
*
gggaagccct ggagacttcc atctgagact gctcccttgg gcttggagac gtctccattg
cccttcggga cctctgaagg tagactctga cgagggaacc cgaacctctg cagaggtaac
BP6-G

►
241

tctgtcctgg gtgcttgcct ggtgggccag aaggttggaa tggggagctg ggctnggcgg
agacaggacc cacgaacgga ccacccggtc ttccaacctt acccctcgac ccganccgcc

intron2/exon3
301

gtctaagctg cctactctcc cttccccagG GCCCATGCCG TAGACATCTG GACTCAGTGC
cagattcgac ggatgagagg gaaggggtcC CGGGTACGGC ATCTGTAGAC CTGAGTCACG
BP6-E

BP6-B

361

TGCAGCAACT CCAGACTGAG GTCTACCGAG GGGCTCAAAC ACTCTACGTG CCCAATTGTG
ACGTCGTTGA GGTCTGACTC CAGATGGCTC CCCGAGTTTG TGAGATGCAC GGGTTAACAC

421

ACCATCGAGG CTTCTACCGG AAGCGGCAGT
TGGTAGCTCC GAAGATGGCC TTCGCCGTCA
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on the human intron 2 genomic sequence determined by our laboratory (unpublished data).
The expected IGFBP-6 hnRNA PCR product was 314 bp in length. The identity of the
PCR product was confirmed and quantitated by southern hybridization with an intron 2
specific probe, BP-6G. (3-actin and IGFBP-6 hnRNA were co-amplified in the same
reaction and p-actin was used as an internal control to normalize IGFBP-6 transcript
levels after southern hybridization. The primer pair and intron specific probe for P-actin
amplification and hybridization are shown in Fig. 27. The sequence was derived from
information published by Nakajima-Iijima et al. (1985). The predicted p-actin hnRNA
PCR product was 331 bp in length. The IGFBP-6 and p-actin primers were designed with
equivalent Tm's so that co-amplification conditions could be more easily optimized.
The total RNA extracted from SaOS-2 cells treated for 24 h with RA was used first
to optimize the RNA concentration and the cycle number for RT-PCR. Total RNA was
treated with DNase I before initiating the reverse transcription reaction to prevent signal
generation from genomic DNA contamination. No PCR products were detected when the
reverse transcription reaction was omitted, suggesting that there are no DNA
contamination (data not shown). Quantitative RT-PCR must be accomphshed within the
linear range of the PCR reaction. Therefore, the linear range with response to RNA
concentration and PCR cycle number was determined. To determine the conditions to
obtain PCR products in a linear range with respect to the amount of RNA added, various
amounts of RNA (125 to 4,000 ng) were added to the RT-PCR reaction. The PCR
reaction was carried out for 20 cycles and IGFBP-6 and P-actin were co-amplified. Fig.
28 shows that the linear range for both IGFBP-6 and P-actin PCR products was obtained
between 125 to 2,000 ng of total RNA. To optimize the amplification cycles, 1,000 ng
RNA was used in the RT-PCR reaction with increasing cycle number ranging from 10 to
30. As shown in Fig. 29, a linear range for both IGFBP-6 and p-actin PCR products was
obtained between 10 to 25 cycles. Therefore, we chose 1,000 ng of RNA and 20 cycles
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Figure 27. The human P-actin gene sequence used for primer and probe preparation
for RT-PCR. The sequence corresponding to exon 3, intron 3 and exon 4 was taken from
Nakajima et al. (1985). Uppercase letters correspond to exon sequence. Lowercase letters
correspond to intron sequence. Arrows show the location of primers and probe sequence
used for intron specific RT-PCR.

125

exon3/intron3

4^
1

AAGGCCAACC GCGAGAAGAT GACCCAGgtg agtggcccgc tacctcttct ggtggccgcc
TTCCGGTTGG CGCTCTTCTA CTGGGTCcac tcaccgggcg atggagaaga ccaccggcgg

61

tccctccttc ctggcctccc ggtgctgcgc cctttctctc tggttctctc ttctgccgtt
agggaggaag gaccggaggg ccacgacgcg ggaaagagag accaagagag aagacggcaa
sense primer

121

ttccgttgga ctctcttctc tgacctgagt ctcctttgga actctgcagg ttctatttgc
aaggcatcct gagagaagag actggactca gaggaaacct tgagacgtcc aagataaacg

181

tttttcccag atgagctctt tttctggtgt ttgtctctct gactaggtgt ctgagacagt
aaaaagggtc tactcgagaa aaagaccaca aacagagaga ctgatccaca gactctgtca

241

gttgtgggtg taggtactaa cactggctcg tgtgacaagg ccatgaggct ggtgtaaagc
caacacccac atccatgatt gtgaccgagc acactgttcc ggtactccga ccacatttcg

-4
inton3 probe
301

ggccttggag tgtgtattaa gtaggcgcac agtaggtctg aacagactcc ccatcccaag
ccggaacctc acacataatt catccgcgtg tcatccagac ttgtctgagg ggtagggttc

361

accccagcac acttagccgt gttctttgca ctttctgcat gtcccccgtc tggcctggct
tggggtcgtg tgaatcggca caagaaacgt gaaagacgta cagggggcag accggaccga

421

intron3/exon4
*
gtccccagtg gcttccccag tgtgacatgg tgcatctctg ccttacagAT CATGTTTGAG
caggggtcac cgaaggggtc acactgtacc acgtagagac ggaatgtcTA GTACAAACTC

-4
antisense primer
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Figure 28. Optimization of the RNA concentration for RT-PCR analysis. SaOS-2
cells were treated with RA (lO-6 M) for 24 h. Total RNA was extracted and treated with
DNase I. Various amounts of RNA ranging from 125 to 4,000 ng were subjected to
RTPCR for 20 cycles to co-amplify IGFBP-6 and (3-actin hnRNAs as described in
Materials and Methods. A 2% TAE agarose gel was used to separate the predicted 314
bp IGFBP-6 and 331 bp (3-actin hnRNA PCR products. The ethidium bromide stained gel
is shown in the upper left panel: lane 1, 1 kb molecular weight ladder; lane 8,
<j)X\ 14/HaelW molecular weight markers. The gel fragments were transferred to Nytran
nylon membrane, hybridized with the labeled intron specific probe for IGFBP-6 or (3-actin
and after washing, the membrane was autoradiographed. The autoradiograph is shown in
the upper right panel. Quantitation of the radioactive signals on the membrane was carried
out with an AMBIS scanner and band intensity was expressed as counts/30 min. The
relationship between the amount of RNA used for RT-PCR and the quantity of IGFBP-6
and (3-actin hnRNA PCR product obtained is shown in the lower panel.

ri
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Figure 29. Optimization of the number of cycles for RT-PCR analysis. Cells were
treated and RNA was extracted as described in Fig. 28. 1,000 ng of total RNA was used
in the RT-PCR to co-amplify IGFBP-6 and P-actin hnRNA with varing PCR cycles
ranging from 10 to 30. The 314 bp IGFBP-6 and 331 bp P-actin PCR products were
separated on a 2% TAE agarose gel as shown in the upper left panel: lane 1, 1 kb
molecular weight ladder; lane 7, fiXll^MHaelW molecular weight markers. The fragments
were transferred and southern blot was hybridized sequencially with the intron specific
probes described in Fig. 28. The results are shown in the upper right panel. Quantitation of
radioactive signals was carried out and the relationship between the number of cycles and
the quantity of PCR product is summarized in the lower panel.
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for the quantitative RT-PCR reactions. No competitive inhibition was observed between
IGFBP-6 and (3-actin in the co-amplification RT-PCR reaction under our experimental
conditions.
To study the effect of RA on IGFBP-6 hnRNA accumulation, SaOS-2 cells were
treated with RA (lO-6 M) or vehicle for 2 h and 24 h, total RNA was extracted, DNase I
treated, and subjected to RT-PCR and southern hybridization as described in the
Materials and Methods section. As shown in Fig. 30, RA did not increase IGFBP-6
hnRNA levels at 2 h, but after 24 h, RA significantly increased IGFBP-6 hnRNA to 6-fold
of control. Previous studies have shown that cycloheximide (CHX) inhibited the increase
in IGFBP-6 mRNA levels. To determine whether CHX affected RA-stimulated IGFBP-6
hnRNA accumulation, SaOS-2 cells were treated with RA (10-6 M) or vehicle in the
presence or absence of CHX (10 jaM) for 24 h, total RNA was extracted and subjected to
RT-PCR and southern analysis as described previously. It was found that CHX
completely abohshed RA-stimulated hnRNA accumulation. The results are shown in Fig.
31. These findings suggest that de novo protein synthesis is required for RA to
efifectivelyincrease IGFBP-6 nascent transcript and mRNA levels.

u>

Figure 30. Effect of RA on IGFBP-6 hnRNA levels in SaOS-2 cells. Cells were treated with RA (10-6 M) or vehicle for 2 and 24
h. Total RNA was extracted and treated with DNase I. 1,000 ng of RNA was used in the RT-PCR reaction to co-amplify IGFBP-6
and p-actin hnRNA for 20 cycles. PCR products were separated on a 2% TAE agarose gel as shown in the left panel: lane 1, 1 kb
molecular weight ladder; lane 6, 0X174/Haelll molecular weight markers. The fragments were transferred to a Nytran nylon
membrane and hybridized with the intron specific probes for IGFBP-6 and P-actin. The result is shown in right panel. The
radioactive bands were quantitated using an AMBIS scanner. The cpm in the IGFBP-6 bands were normalized to the corresponding
cpm in the p-actin bands. The IGFBP-6/p-actin ratio was assigned a value of 1 for control and the ratios for all other samples were
reported as a percentage of this control.
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Figure 31. Effect of cycloheximide on RA-induced IGFBP-6 hnRNA levels in SaOS-2 cells. Cells were treated with RA (10-6
M) or vehicle in the presence or absence of cycloheximide (10 pM) for 24 h. Total RNA was extracted and subjected to RT-PCR
and southern analysis as described in Fig. 30. The left panel illustrates the ethidium bromide stained PCR products and the right
panel illustrates southern analysis of the PCR products. Quantitation of the PCR products was carried out as described in Fig. 30.
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CHAPTER FOUR
IV. DISCUSSION
A. Inhibitory Effect of RA on Human Osteoblast Cell Proliferation and
Differentiation
Two major determinants of bone formation in vivo are osteoblast cell number, which
is dependent on osteoblastic cell proliferation and osteoblast activity, which is dependent
on osteoblastic differentiation. To determine the effects of RA on bone formation, we first
studied its effects on HBC proliferation in vitro and found that RA inhibited the
proliferation of normal HBCs. Our results are similar to previous studies using various
osteosarcoma cell lines. It was reported that RA inhibited the proliferation of rat and
mouse osteosarcoma and chondrosarcoma cells (Ng et al., 1985), human osteosarcoma
TE-85, HS-781 and HS-791 cells and chondrosarcoma HS-705 and HS-819 cells (Thein
et al., 1982). The inhibitory effect of RA on proliferation has also been observed in cells
other than bone, such as human breast cancer cells (Ueda et al., 1980; Fontana et al.,
1988), normal human keratinocytes (Pones et al., 1988) and numerous other malignant
and premalignant human squamous epithelial cells (Meysken et al., 1982). These results
indicate that the inhibitory effect of RA on proliferation is cell type and species
independent. The inhibitory effect of RA on cell proliferation has led to its uses as an
antineoplastic agent.
Because both RA and l,25(OH)2D3 alter gene transcription through nuclear receptor
mediated mechanisms, sometimes involving common cofactors and l,25(OH)2D3 increases
bone cell differentiation, we hypothesized that RA also stimulated bone cell differentiation.
To our surprise, we found that RA inhibited osteoblast phenotype marker expression (eg.
type I procollagen mRNA expression and ALP activity were reduced). This is the first
report describing RA as an inhibitor of human osteoblast differentiation. Previous in vitro
studies reported varying effects of RA on murine osteoblast differentiation which were
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developmental stage dependent (Ng et al., 1988; Heath et al, 1989; Imai et al., 1988). In
our studies, SaOS-2 cells are committed osteoblasts based on the observations that
l,25(OH)2D3 stimulates osteocalcin synthesis, PTH stimulates cAMP formation and
skeletal ALP is expressed (Farley et al., 1989; Wergedal et al., 1984). Therefore, the
inhibitory effect of RA on HBC differentiation is consistent with RA effects on committed
murine osteoblast cells, this suggests that similar mechanisms of RA action could operate
in the two species.
Because l,25(OH)2D3 stimulated, while RA inhibited the expression of osteoblast
differentiation marker proteins, we investigated the combined effects of RA and
l,25(OH)2D3 on the expression of osteoblast differentiation marker proteins. We found
that RA consistently inhibited 1,25(OH)2D3-stimulated type I procollagen, ALP and
osteocalcin mRNA expression as well as ALP activity in SaOS-2 cells. Our findings are
consistent with studies in ROS 17/2.8 rat osteosarcoma cells in which the l,25(OH)2D3
dependent accumulation of osteocalcin mRNA was reduced by all-/ra«s RA as well as
9-cis RA (MacDonald et al., 1993). However, in MG-63 human osteosarcoma cells, RA
increased 1,25(OH)2D3-stimulated osteocalcin expression (Pirskanen et al., 1993).
Differences in osteocalcin expression in response to RA in these cell models could result
from 1) differences in the number or isoform distribution of the RA receptors expressed;
2) differences in the expression of transcription factors, such as AP-1 which interact with
the RA receptors or 3) differences in the regulation of VDR expression. l,25(OH)2D3
mediates its effects on differentiation at least in part through a transcriptional mechanism
with binding of a VDR to a VDRE and involvement of an RXR cofactor (MacDonald et
al., 1993) to increase osteocalcin gene expression, however, a functional VDRE has not
been identified in the ALP gene or type I procollagen gene. Several lines of evidence
suggest that the inhibitory effect of RA on all the osteoblast phenotype markers might
involve regulation of VDR expression directly. In cultures of mouse osteosarcoma cells,
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RA increased ALP activity concurrently with VDR mRNA levels (Suzuki et al., 1993). In
another study, dexamethasone decreased procollagen synthesis, ALP activity and
l,25(OH)2D3-stimulated osteocalcin secretion in rat and human osteoblasts in parallel with
dexamethasone induced decreases in VDR expression (Godschalk et al., 1992). Thus, the
effect of RA on VDR mRNA expression in SaOS-2 cells was investigated to determine if
VDR and osteoblast marker gene expression were reduced parallel. We found that
l,25(OH)2D3 increased VDR expression while RA decreased VDR expression.
Combination treatments with RA and l,25(OH)2D3 decreased l,25(OH)2D3-stimulated
VDR expression to 70% of the levels observed in l,25(OH)2D3-treatment alone. The
reductions in VDR mRNA abundance in RA and l,25(OH)2D3/RA-treated cultures are
small and therefore cannot account entirely for the osteoblast marker changes observed.
These results suggest that the reduction of VDR expression could only in part contribute
to the inhibitory effect of RA on osteoblast cell differentiation.

B. Regulation of the IGF System by RA
Because components of the IGF system can affect proliferation and differentiation, we
tested the hypothesis that RA decreased proliferation and differentiation indirectly by
modulating the IGF system. We systematically studied the effect of RA on IGF system
components expressed in SaOS-2 cells and normal HBCs. The components studied were
IGF-II, IGF-I receptor, IGFBP-3, -4, -5, and -6 (Mohan et al., 1991; Hassager et al.,
1992). We first tested the effect of RA on IGF-II expression. It was reported that of the
multiple IGF-II gene transcripts identified in HBCs, only the 4.9 kb transcript served as a
template for the synthesis of prepro-IGF-II (Nielsen et al., 1990). We found that the
expressions of the 6.0 and 5.3 kb transcripts were significantly increased to 250% and
180% of control by RA, but that the translated 4.9 kb transcript was only increased to
130% of control in SaOS-2 cells. However, in normal HBCs, IGF-II mRNA expression
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was not significantly affected by RA. Because IGF-II protein levels were not measured,
we do not know if IGF-II secretion was increased. Since RA did not significantly
decrease the expression of 4.9 kb IGF-II transcript, we studied the effect of RA on other
IGF system components.
The effects of IGFs on proliferation and differentiation are mediated by two
transmembrane IGF receptors. The IGF-I receptor is a primary mediator of both IGF-I
and IGF-II actions while the IGF-II/M-6-P receptor may mediate some of these functions
but only after IGF-II binding (LeRoith et al., 1995; Redder, 1990). We determined if RA
reduced expression of the IGF receptor. We found that RA significantly decreased both
IGF-I and IGF-II binding to the cell surface of HBCs. Cell surface IGF binding can be
mediated by the IGF-I receptor, the IGF-II receptor and by IGFBP-3 and IGFBP-5
(Mohan et al., 1993). Previous studies of MCF-7 breast cancer cells have demonstrated
that RA increased the IGF-I binding capacity with a concominent increase in the 42 and 46
kDa IGFBPs on the cell surface (Fontana et al., 1991). To begin to distinguish which type
of cell surface IGF binding molecule might mediate this response, we studied the effect of
RA on IGF-I receptor mRNA expression and then on IGFBP expression. RA significantly
decreased IGF-I receptor mRNA levels to 30 % of control within 24 h of treatment in
HBCs. This is the first report describing a RA effect on IGF receptor expression. The 3
fold decrease in IGF-I receptor expression by RA could account for the 3 fold decrease in
IGF-I and IGF-II binding and furthermore could account for the decrease in proliferation
and differentiation. These results did not exclude the possibility that IGFBP expression
was also affected by RA.
The effects of RA on IGFBP expression were tested in nontransformed human
osteoblast cells, osteosarcoma cells and fibroblast cells. We found for the first time that
RA differentially regulated IGFBP expression in human osteoblast and fibroblast cells.
The most striking effect of RA was to increase inhibitory IGFBP-6 mRNA levels more
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than 1,000% of control at 24 h in the four cell types used. IGFBP-6 protein level as
determined by ligand blot analysis was increased by 350% of control by RA treatment
within 48 h. In addition to the effects on IGFBP-6, RA decreased the steady state levels
of IGFBP-5 mRNA in human osteoblast and fibroblast cells. IGFBP-5 protein levels in
the CM of HBCs were also decreased to the same extent after 48 h. IGFBP-3 and -4
mRNA and protein were increased by RA in human osteoblast and fibroblast cells. In
SaOS-2 cells, RA stimulated a dramatic increase in IGFBP-3 mRNA at doses lower than
those required to ebcit responses for IGFBP-4, -5 and -6. The SaOS-2 osteosarcoma cells
responded more to increase IGFBP-3 and -4 than did the HBCs. The reason for the
difference between SaOS-2 cells and HBCs is not clear. In this regard, we have found
that the basal level of IGFBP-3 and IGFBP-4 mRNA in HBCs is higher than the RAstimulated mRNA levels in SaOS-2 cells. These findings raise the possibility that the basal
expression of these two IGFBPs is maximal in HBCs which cannot be further affected by
RA treatment. In summary, the expression of inhibitory IGFBP-3, -4 and -6 was increased
and the expression of stimulatory IGFBP-5 was decreased by RA. Our results are
consistent with previous findings using different cell types. RA increased IGFBP-3 and -4
secretion from human breast cancer cells (Fontana et al., 1991) and human cervical
epithelial cells (Leyen et al., 1994). IGFBP-5 mRNA levels in T47D human breast cancer
cells were decreased by RA (Schmid et al., 1992). RA increased IGFBP-6 proteins levels
in normal and transformed human fibroblast cells (Martin et al., 1994) and increased
IGFBP-6 mRNA levels in MDA-MB-31 human breast cancer cells (Sheikh et al., 1993).
Based on these findings, we conclude that the effect of RA on IGFBP expression is not
specific to osteoblast cells.
The physiological consequence of these alterations in IGFBP expression with
concurrent reduction in IGF-I receptors can only be speculated at this time. The effects,
however, are consistent with the inhibitory action of RA on human osteoblast proliferation

140

and differentiation. In this regard, previous studies from a number of laboratories have
shown that IGFBPs could modulate the biological activity of IGFs both in a positive and
negative manner in a number of cell types including osteoblasts (Shimasaki et al., 1991c;
Redder, 1993). Our previous studies have shown that IGFBP-4 is a potent inhibitor of
IGF actions in bone cells while IGFBP-5 enhanced IGF induced osteoblast cell
proliferation (Mohan et al, 1989; Bautista et al., 1991). Our recent findings also
demonstrate that IGFBP-6 is an inhibitor of IGF-II induced bone cell proliferation
(unpublished observation) and other studies using L6A1 rat myoblast cells demonstrated
that recombinant human IGFBP-6 inhibited IGF-II induced cell differentiation (Bach et al.,
1994). The effect of RA to increase inhibitory IGFBP-4 and -6 and decrease stimulatory
IGFBP-5 as well as IGF-I receptor that we observed, together with the known actions of
these IGFBPs and the IGF-I receptor on osteoblasts suggest that RA mediates its effects
at least in part on cell proliferation and differentiation by decreasing the bio availability and
activity of the IGFs in the osteoblast microenvironment. A model summarizing this
information is shown in Fig. 32.
It was reported that l,25(OH)2D3 inhibited proliferation (Scharla et al., 1993) but
stimulated differentiation (Kyeyune-Nyombi et al., 1991) of human osteoblast cells. Our
findings demonstrated that RA inhibited both proliferation and differentiation of human
osteoblast cells. Although the opposing actions of the two hormones on VDR expression
could in part account for the different effects of RA and l,25(OH)2D3 on osteoblast
differentiation, we speculate that other regulatory factors might also be involved in these
effects. However, our results showed that both RA and l,25(OH)2D3 induced similar
quahtative changes in the expression of several IGF system components although the
magnitude of change was different between the two hormones. The most striking
difference was in the expression of IGFBP-6. In this regard, our data showed that RA but
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not l,25(OH)2D3 increased the expression of IGFBP-6. Because of the differential effects
of RA and l,25(OH)2D3 on IGFBP-6 expression, we speculate that the inhibitory effect of
RA on osteoblast differentaition may in part be mediated through increased IGFBP-6
expression. In support of this speculation, Bach et al. (1994) found that rhIGFBP-6
inhibited IGF-II-induced rat L6A1 myoblast differentiation.

C. Mechanisin(s) by which RA Regulates IGFBP Expression
Previous studies have shown that RA mediates its effects by a variety of mechanisms,
including trans-activation by specific nuclear receptors to alter the rate of gene
transcription (Carson et al., 1990) and more recently by post-transcriptional mechanisms
involving changes in RNA stability or processing (Zhou et al., 1994). Although the
regulation of IGFBP expression by RA has been reported in several other cell types
(Fontana et al, 1991; Leyen et al., 1994; Martin et al., 1994), the molecular mechanism(s)
by which RA regulates the expression of these IGFBPs has not yet been defined. In time
course studies, we found that IGFBP-3, -4 and -6 mRNA did not begin to increase until
approximately 6 h after treatment and maximal increases were not observed until 48 h.
The relatively delayed effect of RA could result from a requirement for de novo protein
synthesis or from a post-transcriptional regulatory mechanism. To distinguish between
these possibilities, we first investigated the effect of RA on the stabilites of IGFBP-3, -4,
-5 and -6 mRNAs. RA increased the IGFBP-3, -4, -5 and -6 mRNA half-fives by 28%,
25%, 117% and 41% of control, respectively. The magnitude of the changes in IGFBP-3
and IGFBP-4 mRNA half-life could account for the increase in their steady-state mRNA
levels. However, the dramatic effects of RA on IGFBP-5 and IGFBP-6 mRNAs could not
be derived solely from effects on mRNA stability. In fact, the change in IGFBP-5 mRNA
levels and its half-life after RA treatment were diametrically opposed. Based on these
findings, we speculated that RA regulated IGFBP-5 and -6 mRNA levels primarily by
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transcriptional or early post-transcriptional mechansims involving nuclear stability,
processing or transport. Cycloheximide abolished the RA-stimulated increase in IGFBP-6
mRNA but did not affect RA-stimulated increases in IGFBP-3 and -4 mRNA levels and
the decrease in IGFBP-5 mRNA. Cycloheximide greatly reduced baseline IGFBP-5
mRNA levels. HBCs produce a number of growth factors (IGF-II and bone morphogenic
proteins) which stimulate IGFBP-5 expression (Knutsen et al., 1995). Cycloheximide
inhibition of endogenous growth factor production could contribute to the reduction in
baseline IGFBP-5 expression.
The most novel finding in this study was the dramatic increase in IGFBP-6 expression
in response to RA which was abohshed by cycloheximide. To determine more about the
mechanism stimulating this increase in IGFBP-6 mRNA, we measured the nascent
IGFBP-6 transcript levels before and after RA treatment with a newly developed intron
specific quantitative RT-PCR assay which specificahy measured the IGFBP-6 and (3-actin
high molecular weight nuclear (hn)RNAs. The RT-PCR assay allowed us to co-amplify
intron specific sequences to study the abundance of IGFBP-6 and P-actin hnRNA primary
transcripts over time in response to RA. Under optimized RT-PCR conditions (within the
linear range of the RNA concentration and cycle number), we found that RA increased
IGFBP-6 hnRNA levels with respect to P-actin to 600% of control at 24 h. Cycloheximide
treatment abolished this effect. Nascent P-actin transcripts were unaffected by either RA
or cycloheximide treatment. These findings demonstrate that RA significantly increases
IGFBP-6 expression by increasing the abundance of its nascent transcript through a
transcriptional or early post-transcriptional mechanism which is dependent on de novo
protein synthesis.
Based on these findings, we proposed a model to illustrate the actions of RA on
IGFBP-6 expression (Fig. 33). According to this model, RA binds to the RAR and this
ligand-receptor complex may have direct effects on IGFBP-6 gene transcription to
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increase IGFBP-6 mRNA level. Consistent with this idea, Zhu et al. (1993) have
reported that the rat IGFBP-6 gene promoter contains an RARE half site. It is not
known, however, whether the human IGFBP-6 gene promoter also contains an RARE.
Since RA treatment increased hnRNA levels and since this effect is dependent on the
synthesis of new protein(s), we also propose that RA treatment leads to increased
expression of UFP. The increased synthesis of this protein may in turn increase IGFBP-6
mRNA levels not only by increasing the stability of hnRNA, but also by increasing
transcription. We beheve that the involvement of UFP in mediating RA actions on
IGFBP-6 mRNA levels is an attractive and testable hypothesis.
The intron specific quantitative RT-PCR technique used to study expression has
distinct advantages over other analytical methodologies. This technique requires much
less RNA to measure nascent transcripts compared to traditional nuclear run-off analysis.
Because of the sensitivity of RT-PCR, only 1 pg of total RNA (derived from 105 cells) is
required for each reaction. This is 2-3 orders of magnitude less than that required for each
data point in a run-off analysis. The intron specific quantiative RT-PCR assay developed
in this study will provide an important analytical tool to study IGFBP-6 gene regulation in
more detail.

D. Conclusion
Over the years, the IGF system was shown to be a primary modulator of proliferation
and differentiation in HBCs. This work provides the first comprehensive investigation of
IGF system regulation in response to RA in human osteoblast cells and provides a clear
mechanism involving the recruitment of specific IGF system components to account for
the RA-induced inhibition of proliferation and differention. The significance of this study
is that it provides an understanding of how RA acts on human osteoblast cells and this
information can be used to help determine the skeletal side effects that would result from
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IGFBP-6 gene has not been cloned or sequenced. Once the IGFBP-6 gene is cloned,
subcloned and sequenced, promoter analysis should be carried out to try to identify
c/5-acting elements and frvms-acting factors that would explain why RA increases
IGFBP-6 hnRNA levels and why l,25(OH)2D3 enhances this response.

APPENDIX
1.

Molecular Biology Solutions
(1) cDNA labeling mix: 1M HEPES, pH 6.6, 0.3 M 2-mercaptoethanol, 15 units

hexanucleotides, 0.2 mM each dNTP (dATP, dGTP, dTTP), 0.025 M Tris-HCl, pH 8.0,
2.5 mM MgCl^ (Feinberg et al., 1983).
(2) Deionized formamide: Formamide was melted at room temperature and 50 mis
was deionized with 5 g AG 501 x 8 resin (BioRad) by stiring for 30 min at room
temperature. The solution was filtered twice with Whatman #1 paper, aliquoted and
stored at -20°C (Ausubel et al., 1994).
(3) Denhardt's 50 x stock: 1% ficoll, 1% polyvinylpyrrolidone, 1% bovine serum
albumin. The solution was then filtered through a disposable 0.22 micro Nalgene filter
(Ausubel et al., 1994).
(4) DEPC water: 0.1% diethyl-pyrocarbonate was added to double-distilled water
for at least 1 h. The treated water was then autoclaved.
(5) Luria broth (LB): 0.1% Bacto-tryptone, 0.05% bacto-yeast extract, 0.1% NaCl,
pH 7.1 (Titus, 1991).
(6) Methylene blue solution: 0.02% methylene blue and 0.3 M sodium acetate, pH
5.5, stored in a dark bottle.
(7) 10 x MOPS: 0.2 M 3-(N-morpholino) propanesulfonic acid, 5 mM sodium
acetate, 5 mM EDTA, pH 7.0 (Ausubel et al., 1994).
(8) Northern sample loading buffer: 720 pi deionized formamide, 320 pi 10 x
MOPS, 260 pi formaldehyde solution (37% stock solution), 100 pi glycerol, 4 mg
bromophenol blue, 4 mg xylene cyanol and 100 pi DEPC water (Ausubel et al, 1994).
(9) Pre-GIT solution: 4 M guanidinium thiocyanate, 0.025 M sodium citrate and
0.5% N-lauryl sarcosine (Ausubel et al., 1994).
(10) GIT solution: 360 pi of 2-mercaptoethanol in 50 ml pre-GIT solution.
150
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(11)5 xfirst strand RT buffer: 0.25 M Tris-HCl, pH 8.3, 0.375 MKC1, 0.015 M
MgCl,.
(12) 10 x NEB Vent buffer: 0.1 M KC1, 0.2 M Tris-HCl, pH 8.8, 0.1 M (NH4)2S04,
0.02 M MgS04, 1% Triton X-100.
(13)20 x SSPE: 3.6 M NaCl, 0.03 M Na^PO^ 0.02 M EDTA, pH 7.4 (Ausubel et
al, 1994).
(14)20 x SSC: 3.0 M NaCl and 3.0 M sodium citrate, pH 7.0 (Ausubel et al., 1994).
(15)50 x TAE: 2 M Tris-acetate and pH 8.0, 0.05 M EDTA (Titus, 1991).
(16) Terrific broth (TB): 1.2% Bacto-tryptone, 2.4% yeast extract and 0.4% glycerol,
17 mM K2HPO4, 72 mM K2HPO4, pH 7.4 (Sambrook et al., 1989).
(17) 10 x TBE: 0.4 M Tris-HCl, pH 8.0, 0.4 M boric acid and 0.012 M EDTA, pH
8.3 (Titus, 1991).
(18) TBE loading buffer: 20% glycerol, 80% 10 x TBE, 0.4% bromophenol blue and
0.4% xylene cyanol (Titus, 1991).
(19)TE buffer: 0.01 M Tris-HCl, pH 8.0, 1 mM EDTA (Titus, 1991).
(20)TENS: 0.1 M NaOH, 0.01 M Tris-HCl, pH 8.0, 1 mM EDTA and 0.1% SDS
(Titus, 1991).
(21) 10 x TMDSE: 0.01 M Tris-HCl, pH 7.6, 0.1 M MgCl^, 0.05 M DTT, 1 mM
spermidine and 1 mM EDTA (Ausubel et al., 1994).

2.

Enzyme Assay, Finding Assay and Protein Analysis Solutions
(1) ALP reaction mix: 0.01 M p-nitrophenol phosphate, 1 mM MgCl^ and 0.015 M

NaC03, pH 10.5 (Kyeyune-Nyombi et al., 1991).
(2) 100 x BSA: 100 mg/ml in distilled water.
(3) Chloramine T solution: 0.05 mg/ml chloramine in 0.3 M sodium phosphate
buffer, pH 7.5.
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(4) IGF binding buffer: 0.02 M HEPES, pH 7.2, 0.1% BSA in DMEM
(Van-Wyk et al., 1985)
(5) IGF lysis buffer: 0.01 M Tris-HCl, pH 7.4, 5 mM EDTA and 0.2% SDS
(Van-Wyk et al., 1985).
(6) Ligand blot solutions (Hossenlopp et al., 1986):
2 x sample buffer: 0.125 M Tris-HCl, pH 6.8, 4% SDS and 20% glycerol.
Running buffer: 0.025 M Tris-HCl, pH 8.3, 0.192 M glycine and 0.1% SDS.
Transfer buffer: 0.025 M Tris-HCl, pH 8.3, 0.192 M glycine.
Washing solution: 0.01 M Tris-HCl, pH 7.4, 0.15 M NaCl, 0.05% sodium azide
and 3% NP-40.
Blocking buffer: 1 % BSA in ligand blot washing solution.
Hybridization buffer: 0.1% Tween 20 in ligand blot washing solution.
Stacking gel: 0.975 ml of mixture containing 30% acrylamide and 2.7%
bis-acrylamide, 1.25 ml 1 M Tris-HCl, pH 6.8, 100 pi 10% SDS, 7.675 ml distilled water,
50 pi 10% ammonium sulfate and 5 pi TEMED.
(7) PBS: 0.137 MNaCl, 0.08 MNa2HP04, 0.027 MKC1, 0.015 MKH^PO^ pH
7.4.

(8) RIA buffer: 0.03 M Na3P04, pH 7.5, 0.25% BSA, 0.02% protamine sulfate,
0.02% sodium azide and 0.01 M EDTA (Mohan et al., 1994).
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